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1. INTRODUCTION 
1.1 Oral Drug Delivery System: 
Oral drug delivery is the most accepted and used route of administration when 
compared to all the other routes that have been known for the delivery of drugs1. 
Conventional oral drug delivery systems releases the drug immediately, in which its 
release of the drug cannot be controlled and cannot maintain effective concentration at 
the site of action or target for longer time2.  These  make  the  way  forward  for  the  
development of other modified release drug delivery system. Most modified release 
delivery system classified into the following categories: 
i. Delayed-release 
ii. Extended-release 
iii. Site-specific targeting 
iv. Receptor targeting 
All modified-release products improves the drug therapy over that achieved with 
their conventional counterparts. There are several potential advantages of modified 
release systems over conventional dosage forms such as  
ü Increase patient compliance 
ü Employ less total drug 
· Eliminate or minimize local side effects. 
· Eliminate or minimize systemic side effects. 
· Reduction or obtain less potentiation in drug activity with chronic use. 
· Minimize drug accumulation with chronic dosing. 
ü Improve efficiency in treatment 
· Cure or control condition promptly. 
· Improve control of condition (reduce fluctuation in drug level). 
· Improve bioavailability3. 
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Figure-1: Drug level versus time profile 4 
 
1.2 Mathematical Models for Controlled-Release Kinetics5: 
From a mathematical modeling point of view, according to physical mechanisms 
of the release of incorporated solute, the controlled-release systems can be classified. The 
majority of controlled-release systems depend on diffusion, dissolution or a combination 
of both to generate slow release of a drug.   A variety of controlled release delivery 
systems are available based on this, they are:  
1. Dissolution – controlled release 
2. Osmotically – controlled release 
3. Diffusion – controlled release 
4. Chemically – controlled release 
5. Miscellaneous – controlled release 
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1.3 Osmotic Controlled Delivery System: 
Osmotic controlled delivery system works under the principle of osmosis. The 
main aim of the modified release is to control the delivery rate of the active ingredient, 
increasing the duration of therapeutic action and/or targeting its delivery to a specific 
tissue. These advances accomplished to the development of osmotic pumps, which are a 
form of a membrane-controlled release drug delivery system by using osmotic pressure as 
the source of energy. The fundamental aspect is that water permeates through a semi-
permeable membrane that allows penetration of water without the active ingredient to 
dissolve its content, which is pushed off6.  
In this delivery system, water soluble active ingredient is combined with excipient 
and covered by a semi-permeable membrane in one chamber tablet. The membrane is not 
permeable to the active pharmaceutical ingredient; a small orifice is made in the coating 
by laser or mechanical during manufacturing. Inside the body, water enters into the tablet 
by osmosis, dissolving the API. The created pressure causes the API solution to go out 
through the hole and the device is therefore described as on osmotic pump dosage form. 
Finally, a steady state is reached where the rate of water entering through the membrane 
is the same as the rate of solution leaving the tablet. For a active moiety with limited 
solubility in water, a two-chamber (push-pull), osmotic pump tablet may be engaged.  
 
 
Figure-2: Schematic cross section of a one chamber osmotic pump7 
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Figure-3: Mechanism of action of a two-chamber osmotic pump tablet7 
 
In the formulated tablet, the API's release rate is dependent largely on the tonicity 
of body fluids. As this is constant, the API can be delivered at a defined rate. Because of 
the same reason, osmotic pump tablets are less exposed to interference from 
physiological conditions such as pH, presence of food. 
The API's desired release rate can be controlled during formulation by modification of: 
ü The nature, surface area, thickness of the semi-permeable coating. 
ü The nature of medium supporting the API. 
ü The orifice size. 
ü The water-swelling osmotic agent's nature. 
Using osmotic pump delivery, the API is released at a steady rate i.e. it tends to 
possess zero order kinetics (i.e. release rate is independent on drug) giving this approach 
an advantage over modified release dosage form. This principle can be used in the 
treatment of hypertension, arthritis and diabetic management7. There are over 357 
patented osmotic drug delivery systems in US, EU, Japan etc.8 
                            
 
Figure-4: Schematic cross-section of a typical osmotic pump implant7 
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1.3.1 Osmosis: 
Osmosis is the net movement of water from an area of high water concentration to 
an area of low water concentration through a semi-permeable membrane. A semi-
permeable membrane is membrane which allows the movement of water but not other 
substances, through it9.  Osmotic pressure is the pressure which, if applied to the more 
concentrated solution side would prevent inward flow of water across the semi-permeable 
membrane. 
The first osmotic effect was reported by Abbe Nollet in 1748, later in 1877, 
Pfeffer performed an experiment using semi-permeable membrane to separate sugar 
solution from pure water. Pfeffer showed that the osmotic pressure of sugar solution is 
directly proportional to solution concentration and the absolute temperature. In 1886, 
Vant Hoff identified an underlying proportionality between osmotic pressure, 
concentration and temperature. He revealed that osmotic pressure is proportional to 
concentration and temperature and the relationship can be described by following 
equation. 
 
Π = Ø c RT 
Where, Ø = osmotic pressure, Π = osmotic coefficient, c = molar concentration, R = gas 
constant, T = absolute temperature10 
 
The osmotic water flow through a membrane is given by the equation11  
dv\dt = A Q Δ π/ L 
Where  
dv/dt = water flow across the membrane of area A in cm2,  
L = thickness,  
Q = permeability and  
Δ π = the osmotic pressure difference between the two solutions on either side of 
the membrane. 
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Figure-5: Principle of osmosis12 
 
 
 
Figure-6: Osmosis 
 (a) Net movement of a solvent from the pure solvent with low solute concentration to a 
solution with high solute concentration;  
(b) osmosis stops when the column of solution on the left becomes high enough to exert 
sufficient pressure at the membrane to counter the net movement of solvent. At this 
point the solution on the left has become more dilute, but there still exists a difference 
in concentrations between the two solutions13 
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1.3.2 Advantages and Disadvantages:  
1.3.2.1  Advantages of Osmotic Controlled Drug Delivery14: 
ü Rate of drug release from osmotic systems is zero-order kinetics. 
ü Osmotic systems provide pulsed or delayed drug release. 
ü In comparison with diffusion controlled systems, osmotic systems attain a 
higher drug delivery rate. 
ü High degree of correlation with in-vivo delivery rate is observed. 
ü Delivery rate is unaffected by pH variations at the site, including the variation 
in the GI tract. 
ü Delivery rate is not affected by agitation from external sources including GI 
motility. 
ü Drug release rate from osmotic system is greatly predictable and 
programmable. 
ü Drug delivery takes place in the solution form, which is equipped for 
absorption, with osmotic pump acting as in-situ liquid dosage form. 
ü Delivery rate is mostly independent of delivery orifice size within limits. 
ü Drugs that exhibit broadly varying solubility pattern can be incorporated. 
1.3.2.1  Disadvantages of Osmotic Controlled Drug Delivery: 
ü The costs of the osmotic devices are considerably higher than matrix tablets 
and multi-particulate capsules. 
ü When an osmotic tablet is subjected to magnetic resonance imaging, in case of 
non-uniform coating it may lead to different patterns of drug release. 
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1.3.3 Classification of Osmotic Drug Delivery System14: 
 A general classification consisting of oral and implantable systems can be 
considered as follows.  
1.3.3.1 Implantable 
1.3.3.2 Oral 
1.3.3.3 Specific types 
1.3.3.1 Implantable Osmotic Pumps: 
1.3.3.1.1 Rose-Nelson Pump 
1.3.3.1.2 Higuchi Leeper Pump 
1.3.3.1.3 Higuchi Theuwes pump 
1.3.3.2  Oral Osmotic Pumps: 
The oral osmotic systems can be of various types which are as follows 
1.3.3.2.1 Single chamber osmotic pump -  Elementary Osmotic Pump 
1.3.3.2.2 Multi chamber osmotic pump -  Push pull osmotic pump 
1.3.3.3  Specific types: 
1.3.3.3.1 Controlled porosity osmotic pump 
1.3.3.3.2 Osmotic bursting osmotic pump 
1.3.3.3.3 Liquid Oral Osmotic System(L-OROS) 
1.3.3.3.4 Delayed delivery osmotic device 
1.3.3.3.5 Telescopic capsule 
1.3.3.3.6 OROS – CT (Colon Targeting) 
1.3.3.3.7 Sandwiched oral therapeutic system 
1.3.3.3.8 Monolithic osmotic systems 
1.3.3.3.9 Multi -Particulate Osmotic Pump 
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1.3.3.1 Implantable Osmotic Pumps: 
1.3.3.1.1 Rose-Nelson Pump15: 
 Rose and Nelson, are the two scientists were the initiators of osmotic drug 
delivery. In 1955, they developed an implantable pump for the drug delivery to the cattle 
and sheep gut. 
 The Rose-Nelson implantable pump shown in figure 7 is composed of 3 chambers 
1. a drug chamber  
2.  salt chamber holding solid salt,  
3. water chamber.  
A semi-permeable membrane separates the salt from water chamber. The water 
movement from the water cavity towards salt cavity is influenced by difference in 
osmotic pressure across the membrane. Possibly, the volume of salt cavity increases due 
to water flow, which swells the latex diaphragm dividing the salt and drug chambers: 
finally, the drug is pumped out of the device. 
 
 
Figure-7: Rose-Nelson Pump15 
 
The pumping kinetics from Rose Nelson pump is given by the following equation: 
dMt / dt=(dV/dt).C, …………….(Eq. 1) 
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where dMt/dt is rate of drug release , dV/dt is volume of water flow into the salt cavity, 
and C represents the concentration of drug in the drug cavity. 
dMt/dt=AθΔπC/l,  …………….(Eq. 2) 
where, A is the area of semi-permeable membrane, Δπ is the osmotic pressure 
gradient, θ is the permeability of semi-permeable membrane, and l is the thickness of 
semi-permeable membrane. These are applicable to the osmotically driven controlled 
drug delivery devices. The saturated solution creats a high osmotic pressure compared to 
that pressure required to pump the suspension of active agent. As a result, the water rate 
entering into the chamber of salt remains stable as long as sufficient solid salt is present 
in die salt chamber to maintain a saturated solution and thereby a constant osmotic 
pressure driving force is created. 
 The major problem associated with Rose-Nelson pumps was that the osmotic 
action began whenever water came in get in touch with with the semi-permeable 
membrane. This wanted pumps to be kept empty and water to be loaded before use. 
1.3.3.1.2 Higuchi-Leeper Osmotic Pump15: 
 Higuchi and Leeper have projected a number of variations of the Rose-Nelson 
pump and they have been described in US patents, which represent the simplifications of 
the Rose-Nelson pump made by the Alza Corporation. One of these pumps is illustrated 
in figure 8. The Higuchi-Leeper pump has no water cavity, and the device activation 
occurs after imbibitions of the water from the adjacent environment. This difference 
permits the device to be prepared loaded with drug and can be kept for long, prior to use. 
This pump contain a firm housing and a semi-permeable membrane supported on a 
perforated frame; a salt cavity containing a fluid solution with an excess of solid salt is 
usually available in this type of pump. Upon administration, nearby biological fluid enter 
into the device through porous and semi-permeable membrane and break downs the 
magnesium sulphate, creating osmotic pressure inside the device which pushes movable 
separator toward the drug cavity to remove drug outside the device. It is broadly used for 
veterinary use. This type of pump is fixed in body of an animal for delivery of antibiotics 
or growth hormones to animals   
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Figure-8: Higuchi Leeper osmotic pump15 
 
 Pulsatile delivery was achieved by using Higuchi Leeper pump; such 
modifications are described and illustrated in Figure 9. The Pulsatile release of drug is 
achieved by drilling the orifice in elastic material that stretches under the osmotic 
pressure. Pulse release of drug is obtained after attaining a certain critical pressure, which 
causes the orifice to open. The pressure then reduces to cause orifice closing and the 
cycle repeats to provide drug delivery in a pulsatile fashion. The orifice should be small 
enough to be substantially closed when the threshold level of osmotic pressure is not 
present. 
 
 
Figure-9: Pulsatile release osmotic pump15 
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1.3.3.1.3 Higuchi-Theeuwes Pump15: 
 Higuchi and Theeuwes in early 1970s developed another variant of the                    
Rose-Nelson pump, even simpler than the Higuchi-Leeper pump as illustrated in Figure 
10.  
 
Figure-10: Higuchi-Theeuwes pump15 
 In this device, the rigid housing consisted of a semi-permeable membrane. This 
membrane is strong enough to withstand the pumping pressure developed inside the 
device due to imbibitions of water. Only prior to its application, the drug is loaded, which 
increases advantage for storage of the device for long time. The drug release from the 
device is managed by the salt used in the salt cavity and the permeability characteristics 
of the outer membrane. 
 Under trade name Alzet made by Alza Corporation in 1976, small osmotic pumps 
of this form are available. They are used frequently as implantable controlled release 
delivery systems in experimental studies requiring continuous administration of drugs. 
Such implantable Alzet pump is shown in Figure 11. 
 
Figure-11: Alzet pump15 
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Figure-12: Higuchi Leeper osmotic pump and Higuchi- Theeuwes pump16 
1.3.3.2 Oral Osmotic Pumps: 
1.3.3.2.1 Elementary Osmotic Pump15:  
 Rose-Nelson pump was more simplified in the form of elementary osmotic 
pump, which made osmotic delivery as a major method of achieving controlled drug 
release. Elementary osmotic pump invented by Theeuwes in 1974 is shown in Figure 13 
and contains an active ingredient having a fitting osmotic pressure. It is made as a tablet 
coated with semi-permeable membrane, usually with cellulose acetate. A small orifice is 
drilled through the membrane coating. While the coated tablet enters to an liquid area, the 
osmotic pressure of the drug inside the tablet draws water through the semi-permeable 
coating and a saturated aqueous solution of drug is made inside the device. The 
membrane is non-extensible and the increase in volume due to imbibitions of water raises 
the hydrostatic pressure inside the tablet, ultimately giving way to flow of solution which 
is saturated of active agent out of the device through a small hole. 
Introduction	
 
	 	Page	14 		
 
 
Figure-13: Elementary osmotic pump17 
The pump initially releases the drug at a rate given by the following equation; 
dMt/dt=(dV/dt).Cs…………….(Eq. 1) 
where, dV/dt represent the flow of water  into the tablet and Cs is the solubility inside the 
tablet. 
1.3.3.2.2 Push-Pull Osmotic Pump (PPOP) 15: 
 Push-pull osmotic pump is an alteration of EOP (Figure 14). Push-pull 
osmotic pump is delivers both poorly water soluble and highly water soluble drugs at a 
constant rate. This system resembles a standard bi-layer coated tablet.  
 
Figure-14: Push-pull based osmotic pump15 
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Figure-15: Cross section of push-pull osmotic pump17 
 One layer (the top one) contains drug in a formulation of polymer, osmogent, and 
other layer contains tablet excipients. This polymeric osmogent has the capacity to form a 
suspension of drug in-situ. When this tablet later imbibes water, the other layer contains 
osmotic and colouring agents, polymer and tablet excipients. These layers are formed and 
attached together by tablet compression to form a single bi-layer core. The core tablet is 
coated with semi-permeable membrane. Once the coating is done, a small hole is placed 
by a laser or mechanical drill on the drug layer side of the tablet.  
Mechanism: 
 When the system is entered in aqueous surrounding, water is attracted into the 
tablet by an osmotic agent in top and bottom layers. The osmotic attraction in the drug 
layer pulls water into the partition to form in-situ a suspension of drug. The osmogent in 
the non-drug layer simultaneously attracts water into that compartment, causing it to 
expand, and the drug suspension is sent out of the delivery orifice by the expansion of 
non-drug layer. 
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Figure-16: Mechanism of push-pull osmotic pump 
 
Figure-17: Push-pull pattern of PPOP tablets upon hydration in dissolution media over time18 
1.3.3.3 Specific Types: 
1.3.3.3.1 Controlled Porosity Osmotic Pump (CPOP) 15: 
 Controlled porosity osmotic pump (CPOP) is shown in Figure 18. It is an 
osmotic tablet wherein the delivery holes are formed in-situ through  escape  of  water  
soluble pore-forming agents included in semi-permeable membrane (SPM) (e.g., urea, 
nicotinamide, sorbitol, etc.). Drug release rate from controlled porosity osmotic pump 
depends on various factors like thickness of coating, drug solubility in tablet core, level 
of leachable pore-forming agent(s) and the osmotic pressure difference across the 
membrane. CPOP system has many advantages. The stomach irritation problems are 
noticeably reduced, as drug is released from the whole of the device surface rather from a 
single hole. Further, no complicated procedure of laser-drilling unit is required because 
the holes are formed in-situ. Scheme describes the drug release phenomenon from a 
typical CPOP.  
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Figure-18 : Controlled porosity osmotic pump19 
1.3.3.3.2 Bursting Osmotic Pump19:  
 There exists a close relationship between osmotic bursting osmotic pumps and 
elementary osmotic pumps. The major differences between the two types of osmotic 
pumps are the absence of a delivery orifice and the small size of the osmotic pump.  
 
Figure-19: Bursting osmotic pump19 
Mechanism of drug release: 
When it is situated in an aqueous surrounding, water is absorbed and 
hydraulic pressure is developed inside the device until the wall bursts and the contents are 
released to the environment. In order to control the release, the thickness and the area of 
the semi-permeable membrane can be altered. 
Advantages: 
 Changing the thickness as well as the area, the semi-permeable membrane can 
control the release of drug. This system is useful to provide pulsated release. 
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1.3.3.3.3 Liquid OROS11: 
Liquid oral osmotic system are designed to deliver the drugs as liquid 
formulations and combine the benefits of extended release with high bioavailability. They 
are of three types:  
· L-OROS hard cap,  
· L-OROS soft cap,  
· Delayed liquid bolus delivery system 
 
 Each system includes a liquid drug layer, an osmotic engine or push layer and 
a semi-permeable membrane coating. When the system is in contact with the aqueous 
environment water permeates across the rate controlling membrane and the osmotic layer 
gets activated. The osmotic layer expands and results in the development of hydrostatic 
pressure inside the system, so the liquid formulation forced to get delivered through the 
delivery orifice. L OROS hardcap or softcap systems provide continuous drug delivery, 
the L OROS delayed liquid bolus drug delivery system is designed to deliver a pulse of 
liquid drug. The delayed liquid bolus delivery system comprises of three layers: a placebo 
delay layer, a liquid drug layer and an osmotic engine, all surrounded by rate controlling 
semi-permeable membrane. The delivery orifice is drilled on the placebo layer end of the 
capsule shaped device. When the osmotic engine expands, the placebo is released first, 
delaying release of the drug layer. Drug release can be delayed from 1 to 10 hours, 
depending on the permeability of the rate controlling membrane and thickness of the 
placebo layer.  
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Figure-20: Liquid OROS19 
 
1.3.3.3.4 Delayed Delivery Based on Multiple Coating20: 
 This osmotic device delivers fluid after a programmed and controllable time 
period. The osmotically driven pump can be made to a size suited for swallowing or 
implanting. This is used to administer a drug in a fluid form after an initial activation 
period during which essentially no drug is administered. The basic components are 
shaped semi-permeable membrane (SPM) that holds an osmotically effective solute and 
drug and a discharge port through which the drug is delivered. A micro-porous outer 
cover surrounds the semi-permeable membrane and protects it from an external aqueous 
environment. A water-swellable composition is kept between the end of the semi-
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permeable membrane and the outer cover. As the pump is placed in an aqueous medium; 
water passes through the micro porous portion of the outer cover into the water swellable 
composition. The water-swellable composition absorbs water and it get expands, in 
piston-like fashion displaces the outer cover, thereby exposing the semi-permeable 
membrane to the aqueous medium and activates the osmotic pump. In initial activation 
period provided by water-swellable composition (time to absorb water, expand, and 
displace the outer cover) during which essentially no drug is delivered by the pump. By 
suitably adjusting the membrane composition and structure, a programmed activation 
period in the range of 3–18 h is achieved. 
 
1.3.3.3.5 Telescopic Capsule20, 21: 
 It is the device for the immediate and extended delivery of an active agent 
during a prolonged period of time. The dispenser comprises first- and second-wall 
sections in a slideable telescoping arrangement (see Figure 21). The device consists of 
two chambers; the first contains the drug and an exit port, and the second contains an 
osmotic engine. The two sections are separated by wax-like material. The desired active 
agent is placed in one section by manual- or automated-fill mechanisms and the delivery 
device, is assembled.  The bi-layer tablet with osmogent engine is kept inside the finished 
cap part of the capsule having osmotic layer with convex is pointed towards the closed 
end of the cap and the barrier layer exposed toward the opening of cap. The open end of 
the filled vessel is fitted inside the open end of the cap, and the two pieces are 
compressed together until the cap, osmotic bi-layer tablet, and vessel fit together tightly. 
 The osmotic engine expands and exhibits pressure on the slideable connected 
first and second wall sections. This happens as fluid is entered through the dispensing 
device. In this delayed period, reservoir volume containing the active ingredient is kept 
constant; so, a minimal pressure gradient is available in between the environment of use 
and the reservoir interior. As a result, the net flow of outside fluid moved by the pressure 
to enter the reservoir is less, and as a result no agent is delivered for the period. 
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Figure-21: Principle of Telescopic capsule15 
 
 
1.3.3.3.6 Colon Targeted Oral Osmotic System (OROS-CT)14: 
 It may consist of single unit osmotic device or as many as five to six osmotic 
unit filled in hard gelatin capsule. Enteric coating is provided for osmotic system. 
Mechanism: 
When GI fluids come in contact with gelatin capsule, shell dissolves. Entry of 
the fluid from stomach to the device is prevented by enteric coating and it dissolves after 
entering into intestine. Upon entry of the water, the push compartment swells and the 
formation of flowable gel happens which is pushed out through delivery orifice at a 
predetermined rate. 
Application: 
· Colon-targeting and  
· Local or systemic therapy. 
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Figure-22: Colon targeted oral osmotic system19 
 
1.3.3.3.7 Sandwiched Osmotic Tablet/Pump (SOT)14: 
The SOT consists of coat and core. The coat consists of a semi-permeable 
membrane with delivery orifice on both the sides; semi-permeable membrane with two-
side delivery orifice. The core tablet comprises of three layers: consists of two layers, 
which are attached, middle push layer with drug. 
Mechanism: 
When placed in the aqueous medium the push layer in middle swells and drug 
releases through delivery orifice. 
 
Figure-23: Sandwiched osmotic tablet19 
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1.3.3.3.8 Monolithic Osmotic Systems11: 
 This Monolithic osmotic system constitutes dispersion of water soluble 
compounds in polymer matrix. Water imbibitions by the active agent takes place when 
this system enters the aqueous region. This happens by rupturing the polymer matrix 
capsule surrounding the drug, thus liberating it out. This process starts occurring at the 
outer region of the polymeric matrix, but later it proceeds towards inside of the matrix. If 
20 –30 volumes per liter of the active agents are incorporated, this system gets failed.  
significant contribution from the simple leaching of the substance take place.  
 
1.3.3.3.9 Multi-Particulate Osmotic Pump20: 
A tablet or capsule having large numbers of pellets bearing two or more 
pellets or particle population belongs to this type of osmotic pump. Every pellet has 
contains the therapeutic drug and a water-soluble osmotic agent as core. Each core 
encloses a water-permeable, water insoluble polymer film. 
Hydrophobic agents that changes permeability (examples are fatty acid, wax, or a salt 
from a fatty acid) are incorporated into the polymer film. The speed of the water passes 
on the core and drug comes out of the core makes the film coating of each pellet to differ 
from the other pellets. The osmogent dissolves in water makes the pellet to swell and 
with that they control the speed of diffusion of drug. Drug released from each pellet 
population into the environment gives a chain of pulsatile administrations of the drug 
from a single dosage form. 
Pellet populations may be varied because of coating thickness. In some cases, 
all of the active moiety in the dosage form may be found in a single population to provide 
a single pulse, which can be delayed by the release-controlling coating. 
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1.4 Formulation of Osmotic Controlled Drug Delivery System: 
 Following are the basic components of osmotic drug delivery system: 
 
1.4.1 Drug14: 
Drugs having less terminal half-life (between 1-6 hours) and potent drugs for 
extended treatment, much suits the requirement of osmotic controlled drug. Various drug 
candidates such as  
· Paliperidone 
· Glipizide  
· Nifedipine are formulated as osmotic delivery. 
 
1.4.2 Osmotic Agent14, 22: 
Osmogents or the osmotic agents maintains the concentration gradient throughout 
the membrane. Pushing force is generated for taking up of water and helps in the 
hydrated formulation by maintaining drug uniformity. Ionic compounds consisting of 
either inorganic salts or hydrophilic polymers are the osmotic components. Sodium 
chloride, sulfates of sodium or potassium and lithium or potassium chloride can be the 
osmotic agents. 
Osmotic agents  can also be as sugars such as inorganic salts of carbohydrates 
glucose, sorbitol, or sucrose. The formulated polymers may be along with poly 
(cellulose), osmotic solutes, or colorants such as ferric oxide. Swellable polymers such as 
poly (alkali carboxy methyl cellulose), poly (ethylene oxide), and poly (alkylene oxide) 
are also included in the push layer of certain osmotic systems. Cyanamer 
(polyacrylamides), Carbopol (acidic carboxypolymer), and Aqua-Keeps (acrylate 
polymer polysaccharides composed of condensed glucose units such as diester cross-
linked polygluran) may be used. 
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Table-1: Osmotic agents and their examples 
Osmogens Example 
Inorganic water-soluble 
osmogens 
Sodium bicarbonate, Sodium sulphate, Magnesium 
sulphate, Sodium chloride, Potassium chloride 
Organic polymer 
osmogens 
Hydroxy propyl methyl cellulose, Sodium carboxy 
methyl cellulose, Polyethylene oxide, Polyvinyl 
pyrrolidine, methyl cellulose 
Carbohydrates 
Arabinose, mannose, galactose, ribose, glucose, 
fructose, sucrose, maltose, lactose, xylose 
Water-soluble amino 
acids 
Alanine, glycine, leucine, methionine 
 
1.4.3 Pore Forming Agents14, 23: 
This pore forming agents are used in the development of controlled porosity or 
multiparticulate osmotic pumps and pumps developed for poorly water-soluble drug.  
Microporous membranes are formed by these agents. Leaching occurs during the 
operation makes the formation of microporus In-situ. The gas formed within the coating 
polymer solution prior to the operation of the device creates pores in the wall. 
 The pore-formers should have the following characteristics: non-toxic, and on 
their removal, channels should be formed. The channels become a transport path for 
fluid. 
· Alkaline metal salts such as sodium chloride, sodium bromide, potassium 
chloride, potassium sulphate, potassium sulphate, potassium phosphate etc. 
· Alkaline earth metals such as calcium chloride, and calcium nitrate. 
· Carbohydrates such as sucrose, glucose, fructose, mannose, lactose, sorbitol, 
mannitol and diols.  
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1.4.4 Wicking Agent22: 
A material with the ability to draw water into the porous network is said as 
wicking agent. It is of either swellable or non-swellable nature. They have the ability to 
undergo physisorption with water. Physisorption is a form of absorption in which the 
solvent molecules can loosely adhere to surfaces of the wicking agent via Vander Waals 
interactions between the surface of the wicking agent and the adsorbed molecule. 
Carrying water to surfaces inside the core of the tablet, and creating channels or a 
network of increased surface area is the function of the wicking agent. 
Wicking agents, include titanium dioxide, sodium lauryl sulphate (SLS), colloidal 
silicon dioxide, kaolin, low molecular weight poly vinyl pyrolidone (PVP), alumina, 
niacinamide, m-pyrol, bentonite, magnesium aluminium silicate, polyester and 
polyethylene. 
1.4.5 Flux Regulating Agents14, 22: 
These are incorporated along with well-forming materials. Regulation of the fluid 
permeability of the flux through the wall is assisted by these agents. They can be 
preselected to enhance or reduce the liquid flux. They also segment the flexibility and 
porosity of the lamina. 
· Flux enhancing agents: hydrophilic substances such as polyethylene glycol 
(300-6000 Da), polyhydric alcohol, poly alkylene glycol. 
· Flux reducing agents: hydrophobic substances such as pthalates substituted 
with an alkyl or alkoxy, example: diethyl phthalate, dimethoxy ethyl 
phthalate. 
1.4.6 Semi-Permeable Membrane11, 14, 23: 
 An important part of the osmotic drug delivery system is the semi-permeable 
membrane. The important feature of semi-permeable membrane utilized for an osmotic 
pump is that it permits only the passage of water into the unit and thereby effectively 
isolate the dissolution process from the gut environment. Therefore, the polymeric 
membrane selection is more important in the osmotic drug delivery formulation. 
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1.4.6.1  Ideal Property of Semi-Permeable Membrane:  
· Membrane should meet some performance criteria:  
· The material must possess sufficient wet strength (-105) and wet modulus to 
retain its dimensional integrity during the operational lifetime of the device.  
· The membrane exhibits sufficient water permeability, so that it retain water 
flux rate in the desired range. The water vapour transmission rates can be used 
to estimate water flux rates. 
· The reflection co-efficient and leakiness of the osmotic agent should approach 
the limiting value of same. Unfortunately, polymer membranes that are more 
permeable to water are also, in general more permeable to the osmotic agent.  
· The membrane should also be biocompatible.  
· Rigid and non-swelling.  
· It should be sufficiently thick to withstand the pressure within the device.  
Polymers that are permeable to water can be used as a coating material in 
osmotic devices example: Cellulose acetate, agar acetate, betaglucan acetate, ethyl 
cellulose, polyether copolymer, olyacetals, polyglcolic acid, polyactic acid, sulfonated 
polystyrenes, polyurethanes. 
 
1.4.7 Coating Solvent2,23: 
Solvents suitable for making polymeric solutions, that is used for manufacturing 
the wall of  the osmotic device include inert inorganic and organic solvents that do not 
adversely harm the core wall and other excipients in osmotic drug delivery. And few 
examples of coating solvent are  methylene chloride, methanol, isopropyl alcohol, 
dichloromethane, ethyl acetate, acetone, carbon tetrachloride, cyclohexane, butyl alcohol, 
water etc and the mixture of solvents such as acetone-methanol(80:20), methylene 
chloride- methanol (79:21), acetone-ethanol (80:20), methylene chloride-methanol-water 
(75:22:3). 
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1.4.8 Plasticizers22: 
Plasticizers lower the temperature of the second order phase transition of the wall 
or the elastic modules of the wall. It also increase the workability, flexibility and 
permeability of the fluids. 
Plasticizer from 0.001 to 50 parts or a mixture of plasticizers are incorporated in 
to 100 parts of wall forming materials. 
Suitable polymers should have a high degree of solvent power for the materials, 
compatible with the materials over both the processing and the temperature range, exhibit 
permanence as seen by their strong tendency to remain in the plasticized wall, impart 
flexibility to the materials and should be non-toxic. 
Examples: dialkyl phthalates and other phthalates, trioctyl phosphates and other 
phosphates, alkyl adipates, triethyl citrate and other citrates, acetates, propionates, 
glycolates, glycerolates, myristates, benzoates, sulphonamides and halogenated phenyls. 
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1.5 General Mechanism For Drug Release From Osmotic Pumps 11: 
 
The basic equation which applies to osmotic systems is  
dM/dt = dV/dt . c …………….(Eq. 1) 
Where,  
dM/dt= mass release,  
dV/dt= volumetric pumping rate,  
c = concentration of drug.  
But, dV/dt = (A/ h) Lp (σ Δπ -Δp) ……………. (Eq. 2) 
Where,  
A = membrane area,  
h = thickness of membrane,  
Lp= mechanical permeability,  
σ = reflection coefficient,  
Δπ = osmotic pressure difference,  
Δp = hydrostatic pressure difference.  
As the size of orifice delivery increases, Δp decrease, so Δπ >> Δp and equation 
becomes  
dV/dt = A/ h Lp (σ Δπ ) …………….(Eq. 3) 
When the osmotic pressure of the formulation is large compared to the osmotic 
pressure of the environment, p can be substituted for Dp.  
dV/dt = A/h Lp σπ = A/hk π …………….(Eq. 4) 
(k = Lpσ = membrane permeability)  
 
Now, equation (1) can be given as  
dM/dt = (A/h) k π c = (A / h) k π S …………….(Eq.5) 
S = solubility of drug, c taken as S 
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1.6 Factors That Influence The Release Rate In The Osmotic Controlled Drug Delivery 
Systems: 
1.6.1 Drug Solubility19: 
 For the osmotic system, solubility of drug is one of the most important parameters 
affecting drug release kinetics from osmotic pumps. The kinetics of osmotic drug release 
is directly related to the drug solubility within the drug core. Assuming that a tablet core 
of pure drug, with zero-order kinetics, the fraction of core released is given by equation. 
F(z) = 1 – S/ρ …………….(Eq. 1) 
Where,  
F(z) is the fraction released by zero-order kinetics,  
S is the drug’s solubility (g/cm3), 
ρ is the density (g/cm3) of the core tablet.  
 
 Drugs with a density of  1 and the solubility of ≤ 0.05 g/cm3 would be released 
with greater than or equal to 95% zero-order kinetics, according to Eq. (1). 
 At the same time, high release rates were demonstrated with highly water-soluble 
drugs that would be zero-order for a small percentage of the initial drug load. Thus, the 
intrinsic water solubility of many drugs might prohibit them from incorporation into an 
osmotic pump. Water solubility of osmotic drugs ranges 50–300 mg/ml.  
 Some of the approaches that have been used to modulate drug solubility within 
the core include: 
(1) co-compression of the drug with excipients, which modulate the drug’s 
solubility within the core. 
(2) Use of effervescent mixtures to increase the release of poorly soluble drug 
from the orifice. 
(3) Use of cyclodextrin derivatives to increase the solubility of poorly water 
soluble drug. 
(4) Use of alternative salt form that has optimum water solubility.  
(5) Use of encapsulated excipients. 
(6) Use of lyotropic crystals.  
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1.6.2 Osmotic Pressure19: 
 The next release-controlling factor that must be optimized is the osmotic pressure 
gradient between the compartment which is inside and the external environment. 
 The release rate of a drug from an osmotic system is directly proportional to the 
osmotic pressure of the core. The simplest and most predictable way to achieve a 
constant osmotic pressure is to maintain a saturated solution of osmotic agent in the 
compartment. If a saturated solution of the drug does not possess sufficient osmotic 
pressure, an additional osmotic agent must be added to the core formulation. The addition 
of carbonate or bicarbonate salt to the drug chamber offers an advantage since the 
effervescent action prevents the precipitated drug from blocking the delivery orifice in 
the tablet. Polymeric osmagents are mainly used in the fabrication of PPOPs and other 
modified devices for controlled release of drugs with poor water solubility. These are 
swellable, hydrophilic polymers that interact with the aqueous fluids and swell or expand 
to an equilibrium state. 
Introduction	
 
	 	Page	32 		
 
Table-2: Osmotic pressure of different compound and its mixture. 
Compound or Mixture Osmotic Pressure (atm) 
Lactose-Fructose 500 
Dextrose-Fructose 450 
Sucrose- Fructose 430 
Mannitol-Fructose 415 
Sodium chloride 356 
Fructose 335 
Lactose-Sucrose 250 
Potassium chloride 245 
Lactose-Dextrose 225 
Mannitol-Dextrose 225 
Dextrose-Sucrose 190 
Mannitol-Sucrose 170 
Sucrose 150 
Mannitol-Lactose 130 
Dextrose 82 
Potassium sulfate 39 
Mannitol 38 
Sodium phosphate tribase 12H2O 36 
Sodium phosphate dibasic 7H2O 31 
Sodium phosphate dibasic 12H2O 29 
Sodium phosphate dibasic anhydrous 29 
Sodium phosphate  monobasic H2O 28 
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1.6.3 Size of Delivery Orifice15: 
To get zero-order delivery profile, area of the orifice must be sufficiently 
large to minimize osmotic pressure build up in the system. Otherwise, the hydrostatic 
pressure can deform the membrane and affect the zero-order delivery rate. Therefore, the 
cross-sectional area of the orifice should be maintained optimum between the minimum 
and maximum values; orifice size is generally between 600 microns to 1 mm. 
Methods to create a delivery orifice in the osmotic systems are: 
1. Mechanical drilling: Done by manually drilling the orifice by special bench top 
equipment or by using needle to get the required diameter of the delivery orifice. 
2. Laser drilling: This technology is well established for producing sub-millimetre 
size hole in tablets. Normally CO2 laser beam is used for drilling purpose, which 
offers excellent reliability. 
3. Indentation: In this type core tablets are made by using modified punches having 
needle on upper punch. The hole made by the indentation is not covered during 
coating process which acts as a path for drug release in osmotic system. 
4. Use of pore forming substances in the semi-permeable membrane coating: e.g. 
controlled porosity osmotic pump. 
1.6.4 Semi-Permeable Membrane19: 
 Some of the membrane variables that are important in the design of oral 
osmotic system are: 
· Type and nature of polymer: 
Any polymer permeable to water but impermeable to solute can be 
selected.  
· Membrane thickness: 
Thickness of the membrane has a marked effect on the drug release from 
osmotic system, which is inversely proportional to each other. 
· Type and amount of plasticizer: 
In pharmaceutical coatings, plasticizers or low molecular weight diluents 
are added to modify the physical properties and improve film-forming 
characteristics of polymers. Plasticizers can change viscoelastic behavior of 
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polymers significantly. In particular, plasticizers can turn a hard and brittle 
polymer into a softer, more pliable material, and possibly make it more 
resistant to mechanical stress. These changes also affect the permeability of 
polymer films. 
1.7 Advances in Osmotic Drug Delivery24: 
Duros Technology: 
The DUROS pump conceptually resembles a miniature syringe in which drug 
is pushed out in highly controlled, minute dosages. Through osmosis, water from the 
body is slowly drawn through the semi-permeable membrane into the pump by salt 
(osmotic agent) residing in the engine compartment. The water drawn into the engine 
compartment expands the osmotic agent and slowly and continuously displaces a 
piston to dispense small amounts of drug formulation from the drug reservoir through 
the orifice. 
 
Figure-24: Duros technology24 
 
DURECT is holding an exclusive license from ALZA Corporation to develop 
and commercialize products in selected fields based on the DUROS® implant 
technology. 
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1.8 Marketed Products19: 
Table -3: Marketed products of osmotic drug delivery system 
Trade Name Active ingredient Design system Dose 
Alpress LP Prazosin Push -Pull 2.5 - 5 mg 
Acutrim Phenylpropanolamine Elementary pump 75 mg 
Cardura XL Doxazosin Push -Pull 4, 8 mg 
Covera HS Verapamil 
Push -Pull with 
time delay 
180, 240 mg 
Ditropan XL Oxybutinin chloride Push -Pull 5, 10 mg 
Dynacirc CR Isradipine Push -Pull 5, 10 mg 
Invega Paliperidone Push -Pull 3, 6, 9 mg 
Efidac 24 
Chlorpheniramie 
maleate 
Elementary Pump 
4 mg IR, 
12 mg CR 
Glucotrol XL Glipizide Push - Pull 5, 10 mg 
Minipress XL Prazocine Elementary pump 2.5, 5 mg 
Procardia XL Nifedipine Push - Pull 30, 60, 90 mg 
Sudafed 24 Pseudoephedrine Elementary pump 240 mg 
Volmax Sabutamol Elementary pump 4, 8 mg 
Tegretol XR Carbamazepine oros 100, 200, 400mg 
Viadur Leuprolide acetate 
Implantable 
osmotic systems 
----- 
Chronogesic Sufentanil 
Implantable 
osmotic systems 
----- 
Concreta Methylphenidate 
Implantable 
osmotic systems 
18, 27, 36, and 
54 mg 
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2. LITERATURE REVIEW 
Suryavanshi V et al., [25] (2016) evaluated push pull osmotic pump-based drug delivery system 
for controlled release of Isoxsuprine hydrochloride for peripheral and cerebral vasodilation. 
Effects of different variables like amount of osmogen, orifice size, coating thickness and 
dissolution media were studied on release profile. Studies concluded that the osmotic pump 
tablets could provide more prolonged and controlled release that may result in an improved 
therapeutic efficacy and patient compliance. 
 
Zala Parth Harishkumar et al., [26] (2015) formulated and evaluated the controlled porosity 
osmotic pump drug delivery for Pregabalin. Controlled porosity of the membrane is 
accomplished by the use of channeling agent. Sodium chloride was used as osmogent. Cellulose 
acetate was used as the semi permeable membrane. The effect of ratio of drug to osmogent, 
membrane weight gain, concentration of pore former, and effect of pH and agitation intensity on 
drug release was also studied. It was found that drug release rate increased with the amount of 
osmogent because of increased water uptake, and hence increased driving force for drug release. 
Drug release was inversely proportional to membrane weight gain: however, directly related to 
the concentration of pore former in the membrane. 
 
Sailaja Reddy Karri et al., [27] (2014) prepared and experimented push-pull osmotic tablets for 
Nateglinide for the treatment of hyperglycemia (type 2 diabetes) which has a half-life of 1.5 h. 
Evaluation studies were performed for weight variation, hardness test and found to be within the 
limit. Dissolution was also performed and the release profile of formulation F is 91.75%, F1 was 
60.89%, F2 was 76.985% and F3 was 83.16% for 12 h. It has been concluded that push-pull 
osmotic tablet was able to deliver the drug in a controlled pattern for a prolonged period. This 
type of formulation can be used in conditions like hyperglycemia where the patient compliance 
can be improved by reducing the dosing frequency and the plasma drug levels can be maintained, 
the total drug load is also reduced so that the dose related side effects are also reduced. 
Millin R Gohel et al., [28] (2014) formulated and optimized a push-pull osmotic controlled drug 
delivery system for highly water soluble drug like ropinirole hydrochloride which can release 
drug in controlled manner for extended period. Push-pull osmotic system showed the desired 
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once-a-day release kinetic. This method may improve patient benefits by providing enhanced 
efficacy and reduced side effects and may also reduce the number of daily doses compared to 
conventional therapies. All the evaluation parameters of tablet like hardness, friability, drug 
content, drug release study, etc. were satisfactory. The stability study revealed that the optimized 
batch which was subjected to accelerated stability study shows no significant changes and 
confirms the stability of formulations.  
 
Patel GC et al., [29] (2014) developed controlled release osmotic pump tablets (COPT) of 
glipizide (GZ) solid dispersion (SD). The SDs having different ratio of drug to Poloxamer 
(PXM) 188 were prepared by hot melt method and optimized by solubility study, drug content 
estimation and in-vitro dissolution study. Effect of two independent variables, amount of 
osmogen (potassium chloride) and hydrophilic polymer (polyethylene oxide WSR 303), were 
investigated using 3 factorial design. Core and coated tablets were evaluated for 
pharmacotechnical parameters. In-vitro drug release profiles of COPT tablets were compared 
with marketed push-pull osmotic pump tablet Prepared core and coated tablets showed 
acceptable pharmacotechnical parameters. Drug release was directly proportional to initial level 
of hydrophilic polymer, but inversely related to the osmogen, confirming osmotic mechanism. 
Zero order drug release pattern was achieved which was comparable to marketed product. Novel 
oral controlled release of glipizide was successfully achieved by incorporating glipizide solid 
dispersion into osmotic system. 
 
Preethi N et al., [30] (2013) developed novel type of elementary osmotic pump [EOP] tablet for 
efficient delivery of poorly water-soluble drug, glipizide. The effect of wetting agent, swelling 
agent, osmotic agent and hydrophobic plasticizer on the release rate were investigated. 
Compared with the marketed Glipizide extended release tablet; GF2 gave the best release rate for 
24 hours. The bioavailability studies for glipizide SEOP and Glipizide extended release tablet 
was carried out in albino rabbits and there was a good in-vivo and in-vitro correlation for GF2 as 
shown by the higher Cmax and AUC values. Thus a novel SEOP was successfully formulated for 
glipizide to achieve zero order drug release over a period of 24 hours. 
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Garvendra S Rathore et al., [31] (2012) developed and evaluated the controlled porosity osmotic 
pump (CPOP) based drug delivery system of sparingly water soluble drug atenolol (ATL). 
Formulation variables, such as, the levels of solubility enhancer (0-15% w/w of drug), ratio of 
the drug to the osmogent, coat thickness of the semi-permeable membrane (SPM) and level of 
pore former (0-20% w/w of polymer) were found to effect the drug release from the developed 
formulations. Cellulose acetate (CA 398-10) was used as the semi-permeable membrane 
containing polyethylene glycol 400 as the plasticizer. ATL release was directly proportional to 
the level of the solubility enhancer, osmotic pressure generated by osmotic agent and level of 
pore former; however, was inversely proportional to the coat thickness of SPM. Drug release 
from developed formulations was independent of the pH and agitation intensities of release 
media. Burst strength of the exhausted shells decreased with increase in the level of pore former. 
The optimized formulations were subjected to stability studies and they were found to be stable 
after 3 months study. 
 
Patel P et al.,[32] (2012) studied the influence of dose and solubility of four model drugs on push-
pull osmotic pumps and found that standard push-pull osmotic pump system may be suitable for 
a wide range of drugs of varying solubility and doses (below 25% w/w of pull layer 
formulation). This investigation demonstrated the robustness and flexibility of the push-pull 
osmotic pump system for various model drugs. 
 
Shahla Jamrzad et al., [33] (2012) studied the influence of level and location of Nacl on 
performance of push pull osmotic pump tablet of a practically water insoluble model drug. Drug 
release profiles were not significantly affected by osmogen concentration in the push layer in the 
range of 10-35% w/w. Presence of osmogen in pull layer resulted in shorter lag time and greater 
drug release rate. The findings of this study illustrated robustness of osmotic technology for zero 
order drug release and approaches to modulate drug release using the osmogen concentration and 
location. 
Sharma AR et al., [34] (2012), developed push pull osmotic drug delivery for a highly insoluble 
drug, they studied the effect of orifice diameter, polymer concentration in drug layer coating 
composition, were tested, and promising results were found. The drug release was independent 
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of pH but dependent on the osmotic pressure of the dissolution medium the release kinetics 
followed the zero order models. 
 
Avinash Singh et al., [35](2011)  developed extended release formulations of Anti diabetic drug 
using osmotic technology and studied the influence of tablet core variables, including amount of 
sodium chloride in drug layer, carbopol 934p amount in push layer and drug layer, effect of ph , 
orifice size, agitation intensity, weight gain by coating, and in-vitro drug release. They observed 
that drug release rate increased significantly as the amount of sodium chloride and carbopol 
increase. Drug release was inversely proportional to the coating thickness, but directly 
proportional to the orifice size. The manufacturing procedure was standardized and found to be 
reproducible. 
 
Afifa Bathool et al., [36] (2011) developed Microporous osmotic tablet of diltiazem 
hydrochloride for colon targeting. The tablets were prepared by wet granulation method and 
coated with microporous semipermeable membrane and enteric polymer using conventional pan 
coating process. The effect of formulation variables was studied by changing the amounts of 
sodium alginate and NaCMC in the tablet core, osmogen, and that of pore-forming agent (SLS) 
used in the semipermeable coating. Drug release was increased as the concentration of osmogen 
and pore-former was increased. Fourier transform infrared spectroscopy and Differential 
scanning calorimetry results showed that there was no interaction between drug and polymers. 
Scanning electron microscopic studies showed the formation of pores after predetermined time 
of coming in contact with dissolution medium. The formation of pores was dependent on the 
amount of pore former used in the semipermeable membrane. In-vitro results showed acid-
resistant, timed release at an almost zero order up to 24 hours. The developed osmotic tablets 
could be effectively used for prolonged delivery of Diltiazem HCl. 
 
Piyush Patel et al., [37] (2011) studied the effect of granulation parameters like inclusion and 
exclusion of milling of dried granules, use of chopper during granulation on the performance of 
push pull osmotic tablet of a practically water insoluble drug. The results of the study showed 
that although differences were observed in the physical properties of the resulting granules drug 
release from the push pull osmotic system was not significantly affected. 
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Shahla Jamzad et al., [38] (2006) developed a new monolithic matrix system to completely 
deliver Anti diabetic drug in a zero order manner. Two approaches were examined using drug in 
formulation that contain swellable hydroxyl propyl methyl cellulose or erodible polyethylene 
oxide. The matrices were prepared by dry blending selected ratios of polymers and ingredients 
using direct compression technique. The interrelationship between matrix hydration, erosion and 
textural properties were determined and analysed under the dissolution test conditions. Hydroxyl 
propyl methyl cellulose matrices showed a significantly greater degree of hydration and swelling 
and stronger texture property relative to polyethylene oxide matrices. Results indicated that in 
the case of low dose/low soluble drug, total drug release in a zero order manner depends on the 
synchronization of erosion and swelling fronts during the entire dissolution study. 
 
Ouyang et al.,[39] (2005) developed a simple elementary osmotic pump system that could deliver 
combinational two Anti diabetic drugs for extended periods of time  in order to reduce the 
problems associated with multidrug therapy of type 2 non-insulin-dependent diabetes mellitus. It 
showed good sustained effect in comparison with the conventional product. The prototype design 
of the system could be applied to other combinations of drugs used for cardiovascular diseases, 
diabetes, etc. 
 
Verma RK et al., [40] (2004) developed and evaluated extended release formulation of glipizide 
based on osmotic technology. The effect of different formulation variables, namely, level of 
solubility modifier in the core, membrane weight gain, and level of pore former in the 
membrane, were studied. Glipizide release was inversely proportional to the membrane weight 
but directly related to the initial level of pore former (PVP) in the membrane. Burst strength of 
the exhausted shells increased with the weight gain of the membrane. On the other hand, burst 
strength decreased with an increase in the level of pore former in the membrane. Results of SEM 
studies showed the formation of pores in the membrane from where the drug release occurred. 
The numbers of pores were directly proportional to the initial level of pore former in the 
membrane. Manufacturing procedure was found to be reproducible and formulations were stable 
after 3 months of accelerated stability studies. 
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Thombre et al.,[41] (2004) developed a swellable-core technology (SCT) formulations that used 
osmotic pressure and polymer swelling to deliver drugs to the GI tract in a reliable and 
reproducible manner. The swellable-core technology formulations consisted of a core tablet 
containing the drug and a water-swellable component, and one or more delivery ports. The           
in-vitro and in-vivo performance of two model drugs, tenidap and sildenafil, formulated in four 
different swellable-core technology core configurations: homogeneous-core (single layer), tablet-
in-tablet, bilayer, and trilayer core were evaluated.  
 
Gan Y et al., [42] (2003) developed Anti diabetic drug – cyclodextrin inclusion complex osmotic 
pump tablets. Polyethylene glycol 4000 and cellulose acetate were selected as the coating 
materials, and acetone–water (95:5) co-solvent was employed as the coating medium. The effects 
of the osmotic promoting agent, diameter of the drug-releasing orifice, coating composition, and 
coat weight on the drug release profile were investigated. The drug release profile of the optimal 
formulation was compared with a commercialized push–pull osmotic tablet. The results indicated 
that Anti diabetic drug–cyclodextrin inclusion complex osmotic pump tablets had excellent zero-
order release characteristics in-vitro. 
 
Zhang Y et al.,[43] (2003) prepared a  novel pulsed-release system based on bilayer coated tablets 
containing an osmotically active agent. Hydroxypropylmethylcellulose and the mixture of 
Eudragit RS and RL were applied as the swelling layer and semi permeable outer coat, 
respectively. To examine the mechanism of drug release from this pulsed-release system, drug 
release behaviors were investigated under conditions of various osmotic pressures. Both lag time 
and release rate were dependent on the coating level and the osmotic pressure of the dissolution 
medium. 
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3. AIM AND OBJECTIVE 
3.1 Aim 
Ø To develop and evaluate a push-pull based osmotic delivery system for anti-diabetic 
drug (Glipizide). 
3.1.1 Objective 
Ø To develop push-pull based osmotic delivery system of anti-diabetic drug, 
belonging to BCS class II and optimize a generic formulation to the innovator. 
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4. Work Plan 
4.1 Pre-formulation studies 
4.1.1 Organoleptic properties 
4.1.2 Solubility 
4.1.3  Melting point 
4.1.4  X-ray diffraction 
4.1.5  Hygroscopic studies 
4.1.6  Sieve analysis 
4.1.7  Moisture content of API 
4.1.8  Density: 
4.1.8.1 Bulk Density 
4.1.8.2 Tapped density 
4.1.8.3 Carr’s Index 
4.1.8.4 Hausner’s Ratio 
4.1.8.5 Angle of repose 
4.1.9 Drug-Excipient compatibility study 
4.2 Characterization of Innovator Product 
4.2.1 Physical Properties  
4.2.1.1 Description 
4.2.1.2 Average weight 
4.2.1.3 Thickness 
4.2.1.4 Hardness 
4.2.1.5 Dissolution profile 
4.3 Analytical parameters 
4.3.1 Determination of ʎmax 
4.3.2 Plotting of calibration curve 
4.4 Formulation of OCDDS 
4.4.1 Optimization of core tablet formula 
4.4.1.1 Optimization of PEO in push and pull layers 
4.4.1.2 Optimization of osmogent in push layer 
4.4.2 Optimization of the semi permeable membrane (coating of the core tablet) 
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4.5 Evaluation of Osmotic tablets  
4.5.1 Assay 
4.5.2 Weight variation 
4.5.3 Hardness 
4.5.4 Friability 
4.5.5 Thickness 
4.5.6 Coating uniformity 
4.5.7 In-vitro drug release and comparison with innovator 
4.6 Evaluation of Osmotic tablets  
4.6.1 Comparison of dissolution testing between innovator and prepared Anti-
diabetic tablets. 
4.7 Stability studies 
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5. SCOPE OF THE WORK 
  Osmotically controlled drug delivery systems (OCDDS), is a novel drug delivery 
system that utilizes the principles of osmotic pressure for the controlled delivery of drug. 
Osmotic devices are most promising strategy based system for controlled drug delivery and are 
designed to follow true zero-order kinetics and thus high degree of in-vitro / in-vivo correlation 
can be achieved. 
  Drug  release  from  these  systems  is  also  independent  of  pH,  food  and  
hydrodynamic conditions of the gastro-intestinal tract (GIT) to a large extent, and release 
characteristics can be easily adjusted by optimizing the parameters of the delivery system.  
  An anti-diabetic drug, Glipizide falling under BCS class-II drug was selected for 
the development of OCDDS due to its short biological half-life (2-4 hrs), high potency, and need 
for prolonged treatment. 
  Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class to 
improve glycemic control as an adjunct to diet in adults with type 2 diabetes mellitus, a BCS 
Class-II drug.  
  The conventional formulation of this drug possesses problems like frequent 
dosing and large fluctuation in drug plasma concentration. Moreover, it may cause adverse 
gastrointestinal reactions. This indicates need to develop controlled release formulations for 
these drugs. Thus, OCDDS was selected for development of CR formulation of these drugs. 
  In the present study double chambered Push Pull Osmotic Pump (PPOP) is 
chosen, because this technique is proved as simple, inexpensive and having industrial feasibility. 
This system relies on semi permeable membrane to function. This system is characterized by the 
different parameters like weight variation, hardness, friability, drug content, and In vitro drug 
release studies etc. 
  Thus, the scope of present study was to formulate, optimize and characterize 
osmotically controlled drug release systems for selected drug using Push Pull Osmotic Pump 
(PPOP) technique. Optimized batch was subjected stability study as per ICH guidelines. The 
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study also focused comparison of developed formulation made by innovator and identifying 
optimized generic formulation to innovator.  
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6. DRUG AND EXCIPIENT PROFILE 
6.1 Drug Profile44: 
Drug Name:    Glipizide 
Chemical Structure: 
 
Figure-25: Structure of Glipizide 
Chemical Name:  1-cyclohexyl-3-[[p-[2-(5 ethylpyrazinecarboxamido) ethyl] 
phenyl] sulfonyl] urea 
Chemical Formula:   C21H27N5O4S 
Molecular Weight:   445.55 
Category:    Anti-diabetic 
Description:     Whitish, odorless powder 
Solubility:  It is insoluble in water and alcohols, but soluble in 0.1 N 
NaOH; it is freely soluble in dimethyl formamide. 
Strengths:     2.5mg, 5mg and 10mg. 
BCS Class:    Class II (Low Soluble – High Permeable) 
Pharmacokinetics:  Gastrointestinal absorption of Glipizide in man is uniform, rapid, 
and essentially complete.  Peak plasma concentrations occur 1–3 hours after a single oral 
dose. The elimination half-life ranges from 2–4 hours in normal subjects, whether given 
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intravenously or orally. The metabolic and excretory patterns are similar with the two 
routes of administration, indicating that first-pass metabolism is not significant. Thus, 
Glipizide was more effective when administered about 30 minutes before, rather than 
with, a test meal in diabetic patients. Protein binding found to be 98–99% one hour after 
either route of administration. The metabolism is extensive and occurs mainly in the 
liver. Less than 10% unchanged glipizide is found in the urine. 
Mechanism of Action: The primary mode of action of Glipizide in experimental animals 
appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet 
tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans, 
Glipizide appears to lower the blood glucose acutely by stimulating the release of insulin 
from the pancreas, an effect dependent upon functioning beta cells in the pancreatic 
islets. The mechanism by which glipizde lowers blood glucose during long-term 
administration has not been clearly established. In man, stimulation of insulin secretion 
by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin 
levels are not elevated even on long-term glipizide administration, but the postprandial 
insulin response continues to be enhanced after at least 6 months of treatment. The 
insulinotropic response to a meal occurs within 30 minutes after an oral dose of glipizide 
in diabetic patients, but elevated insulin levels do not persist beyond the time of the meal 
challenge. Extra pancreatic effects may play a part in the mechanism of action of oral 
sulfonylurea hypoglycemic drugs. 
Indication and Dosage: Management of type 2 diabetes (Non Insulin Dependent 
Diabetes Mellitus) where diet control alone is not effective in controlling the 
hyperglycemia. Dosage should be given to patients individually, on basis of periodic tests 
of glycosuria and blood sugar. The maximum daily dose should not exceed 30 mg as 
maintenance dose. 
Contraindication: Glipizide is contraindicated in Insulin dependent diabetes mellitus, 
diabetic-keto-acidosis, diabetic coma, pregnancy, in subjects with severely impaired 
kidney or liver function, adrenal insufficiency and cases of confirmed individual 
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hypersensitivity to the drug, latent diabetes or pre-diabetic states, the use of sulfonylurea 
is not advisable.  
Interaction: The hypoglycemic actions of sulfonylurea may be potentiated by certain 
drugs including nonsteriodal anti-inflammatory drugs and other drugs that are highly 
protein bound salicylates, sulphonamides and chlormphenicol. When such drugs are 
administered to a patient receiving glipizide, the patient should be observed for 
hypoglycemia. 
Side Effects: Hypoglycemia, gastrointestinal disturbances (nausea and diarrhea, one in 
seventy; constipation and gastralgia, one in one hundred), allergic reactions (erythema, 
morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been 
reported in about one in seventy patients), dizziness, drowsiness, and headache have each 
been reported in about one in fifty patients treated with glipizide. 
Precaution: Patients should be instructed to closely follow their physician’s prescription 
with regard to diet, dosage and schedule for taking the drug and should be taught to 
recognize promptly the early symptoms of hypoglycemia, that generally are headache, 
irritability, sleep disorders, tremor and heavy sweating, so they can contact a doctor in 
good time.   
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6.2 Excipient Profile45: 
6.2.1 Poly Ethylene Oxide: 
Table -4: Poly Ethylene Oxide Profile 
Non-proprietary 
Names: 
USP-NF: Polyethylene Oxide 
Synonyms : 
Polyox; polyoxiante;  
polyoxirane; polyoxyethylene. 
Chemical Name and 
CAS Registry 
Number: 
Polyethylene oxide [25322-68-3] 
Empirical Formula:  
(CH2CH2O) n, where n represents the average number of  
oxyethylene groups. 
Molecular Weight: 1 lakh to 70 Lakhs depends on their grade. 
Structural Formula:  
 
Description:   
White to off-white, free-flowing powder. Slight ammoniacal 
odor. 
Functional Category: Mucoadhesive; coating agent; tablet binder; thickening agent. 
Applications:   
Polyethylene oxide can be used as a tablet binder at 
concentrations of 5–85%. The higher molecular weight grades 
provide delayed drug release via the hydrophilic matrix 
approach. Low levels of polyethylene oxide are effective 
thickeners, although alcohol is usually added to water based 
formulations to provide improved viscosity stability. 
Polyethylene oxide films demonstrate good lubricity when wet. 
Typical Properties: 
Angle of repose:   34º 
Density (true): 
  
1.3g/cm3 
Melting point: 65–70º C 
Moisture content:   <1% 
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Solubility: 
Polyethylene oxide is soluble in water and a number of common 
organic solvents such as acetonitrile, chloroform, and methylene 
chloride. It is insoluble in aliphatic hydrocarbons, ethylene 
glycol, and most alcohols. 
Stability and Storage 
Conditions: 
Store in tightly sealed containers in a cool, dry place. Avoid 
exposure to high temperatures since this can result in reduction 
in viscosity.  
Incompatibilities  
 
 Polyethylene oxide is incompatible with strong oxidizing 
agents. 
Related Substances: Polyethylene glycol. 
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6.2.2 Sodium Chloride: 
Table-5: Sodium Chloride Profile 
Non-proprietary 
Names: 
BP: Sodium Chloride 
JP: Sodium Chloride 
PhEur: Sodium Chloride 
USP: Sodium Chloride 
Synonyms: 
Alberger; chlorure de sodium; common salt; hopper salt; 
natural halite; rock salt; saline; salt; sea salt; table salt. 
Chemical Name and 
CAS Registry 
Number: 
Sodium chloride [7647-14-5] 
Empirical Formula:  NaCl 
Molecular Weight: 58.44 
Structural Formula:  Cl-----Na+ 
Description:   
Sodium chloride occurs as a white crystalline powder or 
colorless crystals; it has a saline taste. 
Functional Category: Tablet and capsule diluent; tonicity agent; 
Applications:   
Sodium chloride has also been used as a channeling agent and 
as an osmotic agent in the cores of controlled-release tablets. 
Typical Properties: 
Acidity/alkalinity: pH = 6.7–7.3 (saturated aqueous solution) 
Angle of repose:  38º for cubic crystals 
Boiling point  1413ºC 
Melting point: 804ºC 
Density:  2.17 g/cm3; 1.20 g/cm3 for saturated aqueous solution. 
Solubility: In Water 1 in 2.8 at 20 ºC and 1 in 2.6 at 100ºC 
Stability and Storage 
Conditions: 
Aqueous sodium chloride solutions are stable but may cause 
the separation of glass particles from certain types of glass 
containers. Aqueous solutions may be sterilized by autoclaving 
or filtration. The solid material is stable and should be stored in 
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a well-closed container, in a cool, dry place. It has been shown 
that the compaction characteristics and the mechanical 
properties of tablets are influenced by the relative humidity of 
the storage conditions under which sodium chloride was kept. 
Incompatibilities:  
 
Aqueous sodium chloride solutions are corrosive to iron. They 
also react to form precipitates with silver, lead, and mercury 
salts. Strong oxidizing agents liberate chlorine from acidified 
solutions of sodium chloride. 
Related Substances: Potassium chloride. 
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6.2.3 Cellulose, Microcrystalline:  
Table-6: Cellulose, Microcrystalline Profile 
Non-proprietary 
Names: 
BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
Synonyms: 
Avicel PH; Cellets; Celex; cellulose gel; hellulosum 
microcristallinum; Celphere; Ceolus KG; crystalline cellulose; 
E460; Emcocel; Ethispheres; Fibrocel; MCC Sanaq; Pharmacel; 
Tabulose; Vivapur. 
Chemical Name and 
CAS Registry 
Number: 
Cellulose [9004-34-6] 
Empirical Formula:  C6H10O5) n where n _ 220. 
Molecular Weight: 36000 
Structural Formula:  
 
Description:   
Microcrystalline cellulose is a purified, partially depolymerized 
cellulose that occurs as a white, odorless, tasteless, crystalline 
powder composed of porous particles. It is commercially 
available in different particle sizes and moisture grades that 
have different properties and applications. 
Functional Category: 
Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrant. 
Applications:   
Microcrystalline cellulose is widely used primarily as a 
binder/diluent in oral tablet and capsule formulations where it is 
used in both wet-granulation and direct-compression processes. 
In addition to its use as a binder/diluent, microcrystalline 
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cellulose also has some lubricant and disintegrant properties 
that make it useful in tableting. 
Typical Properties: 
Angle of repose:  Ceolus KG: 49º and Emcocel 90M: 34.4º 
Density: 
Bulk: 0.32 g/cm3 for Avicel PH-101; Tapped: 0.45 g/cm3 for 
Avicel PH-101; 
Specific surface area: 1.06–1.12m2/g for Avicel PH-101 
Melting point: Chars at 260-270 º C 
Solubility: 
Slightly soluble in 5% w/v sodium hydroxide solution; 
practically insoluble in water, dilute acids, and most organic 
solvents. 
Stability and Storage 
Conditions: 
Microcrystalline cellulose is a stable though hygroscopic 
material. The bulk material should be stored in a well-closed 
container in a cool, dry place. 
Incompatibilities:  
Microcrystalline cellulose is incompatible with strong oxidizing 
agents. 
Related Substances: 
Microcrystalline cellulose and carrageenan; microcrystalline 
cellulose and carboxymethylcellulose sodium; microcrystalline 
cellulose and guar gum; powdered cellulose; silicified 
microcrystalline cellulose. 
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6.2.4 Magnesium Stearate:  
Table-7: Magnesium Stearate Profile 
Non-proprietary 
Names: 
BP: Magnesium Stearate 
JP: Magnesium Stearate 
PhEur: Magnesium Stearate 
USP-NF: Magnesium Stearate 
Synonyms: 
Dibasic magnesium stearate; magnesium distearate; magnesii 
stearas; magnesium octadecanoate; octadecanoic acid, 
magnesium salt; stearic acid, magnesium salt; Synpro 90. 
Chemical Name and 
CAS Registry 
Number: 
Octadecanoic acid magnesium salt [557-04-0] 
Empirical Formula:  C36H70MgO4 
Molecular Weight: 591.24 
Structural Formula:  [CH3(CH2)16COO]2Mg 
Description:   
Magnesium stearate is a very fine, light white, precipitated or 
milled, impalpable powder of low bulk density, having a faint 
odor of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin. 
Functional Category: Tablet and capsule lubricant. 
Applications:   
Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations. It is primarily used as a lubricant 
in capsule and tablet manufacture at concentrations between 
0.25% and 5.0% w/w. 
Typical Properties: 
Flowability: Poorly flowing, cohesive powder. 
Density: Bulk: 0.159 g/cm3; Tapped: 0.286 g/cm3 
Specific surface area: 1.6–14.8m2/g 
Melting point: 117-150ºC 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; 
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slightly soluble in warm benzene and warm ethanol (95%). 
Stability and Storage 
Conditions: 
Magnesium stearate is stable and should be stored in a well-
closed container in a cool, dry place. 
Incompatibilities:  
 
Incompatible with strong acids, alkalis, and iron salts. Avoid 
mixing with strong oxidizing materials. Magnesium stearate 
cannot be used in products containing aspirin, some vitamins, 
and most alkaloidal salts. 
Related Substances: 
Calcium stearate; magnesium aluminum silicate; stearic acid; 
zinc stearate. 
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6.2.5 Iron Oxide (Yellow):  
Table-8: Iron Oxide (yellow) Profile 
Non-proprietary 
Names: 
None adopted. 
Synonyms: 
E172; hydrated ferric oxide; iron (III) oxide monohydrate, 
yellow; pigment yellow 42; yellow ferric oxide. 
Chemical Name and 
CAS Registry 
Number: 
Iron oxide yellow [51274-00-1] (monohydrate); [20344-49-4] 
(hydrate) 
Empirical Formula:  Fe2O3_H2O (monohydrate); FeHO2 (hydrate) 
Molecular Weight: Monohydrate - 177.70; hydrate - 88.85 
Structural Formula:  
Iron oxides are defined as inorganic compounds consisting of 
any one of or combinations of synthetically prepared iron 
oxides, including the hydrated forms. 
Description:   
Iron oxides occur as yellow, red, black, or brown powder. The 
color depends on the particle size and shape, and crystal 
structure. 
Functional Category: Colorant. 
Applications:   Colorant. 
Typical Properties: 
Density: 4.1 g/cm3 
Melting point: 1565ºC 
Solubility: Soluble in mineral acids; insoluble in water 
Stability and Storage 
Conditions: 
Iron oxides should be stored in well-closed containers in a cool, 
dry place. 
Incompatibilities:  
 
Iron oxides have been reported to make hard gelatin capsules 
brittle at higher temperatures when the residual moisture is 11–
12%. 
Related Substances: - 
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6.2.6 Opadry® CA:  
Table-9: Opadry CA Profile 
Opadry® CA, a ready formulated SPM coating system comprising Cellulose Acetate and 
Poly Ethylene Glycol 335046 
 Cellulose Acetate Poly Ethylene Glycol 
Non-
proprietary 
Names: 
BP: Cellulose Acetate 
PhEur: Cellulose Acetate 
USP-NF: Cellulose Acetate 
BP: Macrogols 
JP: Macrogol 400, Macrogol 1500 
Macrogol 4000, Macrogol 6000 
Macrogol 20000 
PhEur: Macrogols 
USP-NF: Polyethylene Glycol 
Synonyms: 
Acetic acid, cellulose ester; 
acetyl cellulose; cellulose 
diacetate; cellulose triacetate; 
cellulosi acetas. 
Carbowax; Carbowax Sentry; 
Lipoxol; Lutrol E; macrogola; PEG; 
Pluriol E; polyoxyethylene glycol. 
Chemical 
Name and 
CAS Registry 
Number: 
Cellulose acetate [9004-35-7] Poly ethylene glycol [25322-68-3] 
Empirical 
Formula:  
[C6H7O2(OH)3-
m(OOCCH3)m], m = 0~3 
HOCH2(CH2OCH2)mCH2OH where 
m represents the average number of 
oxyethylene groups. 
Molecular 
Weight: 
38000 - 60000 PEG 3350: 3000 - 3700 
Structural 
Formula:  
 
Description:   
Cellulose acetate occurs as a 
hygroscopic white to off-
Polyethylene glycol grades 200–600 
are liquids; grades 1000 and above 
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white, free flowing powder, 
pellet, or flake. It is tasteless 
and  odorless,  or  may  have  a  
slight odor of acetic acid. 
are solids at ambient temperatures. 
Solid grades (PEG>1000) are white 
or off-white in color, and range in 
consistency from pastes to waxy 
flakes. They have a faint, sweet odor. 
Grades of PEG 6000 and above are 
free flowing milled powders. 
Functional 
Category: 
Coating agent; extended-
release agent; tablet and 
capsule diluent. 
Ointment base; plasticizer; solvent; 
suppository base; tablet and capsule 
lubricant. 
Applications:   
Cellulose acetate is used as a 
semipermeable coating on 
tablets, especially on osmotic 
pump-type tablets and 
implants. 
Polyethylene glycols can also be used 
to enhance the aqueous solubility or 
dissolution characteristics of poorly 
soluble compounds by making solid 
dispersions with an appropriate 
polyethylene glycol. 
Typical Properties: 
Density: 0.4 g/cm3 for powders. 1.15–1.21 g/cm3 at 25ºC 
Melting point: 200-300ºC 48–54ºC for PEG 3000 
Solubility: 
The solubility of cellulose 
acetate is greatly influenced by 
the level of acetyl groups 
present. In general, cellulose 
acetates are soluble in acetone–
water blends of varying ratios, 
dichloromethane–ethanol 
blends, dimethyl formamide, 
and dioxane. 
Solid polyethylene glycols are soluble 
in acetone, dichloromethane, ethanol 
(95%), and methanol; they are 
slightly soluble in aliphatic 
hydrocarbons and ether, but insoluble 
in fats, fixed oils, and mineral oil 
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Stability and 
Storage 
Conditions: 
Cellulose  acetate  is  stable  if  
stored in a well-closed 
container in a cool, dry place. 
Cellulose acetate hydrolyzes 
slowly under prolonged 
adverse conditions such as high 
temperature and humidity, with 
a resultant increase in free acid 
content and odor of acetic acid 
Polyethylene glycols are chemically 
stable in air and in solution, although 
grades with a molecular weight less 
than 2000 are hygroscopic. 
Polyethylene glycols should be stored 
in well-closed containers in a cool, 
dry place. Stainless steel, aluminum, 
glass, or lined steel containers are 
preferred for the storage of liquid 
grades. 
Incompatibili-
ties:  
Cellulose acetate is 
incompatible with strongly 
acidic or alkaline substances. 
Cellulose acetate is compatible 
with the following plasticizers: 
diethyl phthalate, polyethylene 
glycol, triacetin, and triethyl 
citrate. 
Liquid and solid polyethylene glycol 
grades may be incompatible with 
some coloring agents. 
Related 
Substances: 
Cellulose acetate phthalate. 
Polyoxyethylene alkyl ethers; 
polyethylene oxide; polyoxyethylene 
sorbitan fatty acid esters; 
polyoxyethylene stearates; 
suppository bases. 
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7. MATERIALS AND METHODS 
7.1 Materials And Equipments: 
7.1.1 List of Materials: 
Table-10: List of materials used 
S. No. Materials Used Manufacturer Functional Category 
1.  Anti-Diabetic Drug Sri Krishna Drugs Limited, Hyderabad, India 
Active Pharmaceutical 
Ingredient 
2.  Poly ethylene oxide          (6 lakhs MW) Colorcon
®, Goa, India Controlled release polymer 
3.  Poly ethylene oxide             (3 lakhs MW) Colorcon
®, Goa, India Controlled release polymer 
4.  Poly ethylene oxide             (50 lakhs MW) Colorcon
®, Goa, India Controlled release polymer 
5.  Poly ethylene oxide              (70 lakhs MW) Colorcon
®, Goa, India Controlled release polymer 
6.  Sodium Chloride Merck KGaA, Darmstadt, Germany 
Channelizing Agent & 
Osmotic agent 
7.  Iron oxide -yellow Firmenich Inc., New Jersy, USA Colorant 
8.  Opadry CA Colorcon®, Goa, India Semi-permeable coat 
9.  Opadry pink Colorcon®, Goa, India Top coat 
10.  Magnesium Stearate USP NF 
Covdien Mallinckrodt, 
Missouri, USA Lubricant 
11.  
Microcrystalline 
cellulose                     
(Avicel PH-101) 
FMC Corporation health and 
Nutrition, Newark, USA Diluents 
12.  Ethanol Hayman Ltd, Essex, UK Solvent 
13.  Acetone Vertullus Performance, Grensboro, USA Solvent 
14.  Water Purified water Solvent 
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7.1.2 List of Equipments: 
Table-11: List of Equipments used 
S. No. Equipments Used Manufacturer 
1.  Electronic Weighing balance Mettler Toledo, India 
2.  Sieve shaker Retsch, Germany 
3.  Rapid mixer granulator Sams, India 
4.  Rapid Dryer Retch, USA 
5.  Moisture Analyser Sartorius, Germany 
6.  Mechanical Sifter Gansons, India 
7.  Multi Mill Gansons, India 
8.  Octagonal Blender Sams Techno Mech, India 
9.  USP Tap density tester Electrolab, India 
10.  Compression machine (16 stations) Cadmach, India 
11.  Digimatic vernier caliper Mitotoyo, Japan 
12.  Friability Test Apparatus Electrolab, India 
13.  Varian Hardness tester Varian Inc, USA 
14.  Mechanical stirrer Remi stirrers, India 
15.  Coating Machine Sams, India 
16.  Dissolution apparatus Electrolab, India 
17.  UV Spectrophotometer Perkin Elmer, USA 
18.  Differential Scanning Calorimeter Universal V4.5A,  TA instruments, Delaware, USA 
19.  X-Ray Diffractometer D8 Advanced, Bruker Axs, Germany 
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7.2 Pre-Formulation Studies:  
 The following attributes were considered for API before initiating the formulation 
development: 
Ø Chemical characteristics: Solubility and Stability 
Ø Physical Characteristics: Particle size, flow characteristics, bulk density 
Ø Formulation Characteristics: Assay, Friability, hardness, tablet weight, 
thickness, and effect of formulation variables on the dissolution profile. 
 A detailed understanding of the properties of drug substances is essential for 
minimizing formulation problems in later stage of drug development which will 
ultimately help in reducing the drug development cost and in decreasing time to reach the 
market.  
 The goal of the pre-formulation studies is to choose the correct form of the drug 
substance, to evaluate the physicochemical properties of drug and to generate a thorough 
understanding of the stability of the active pharmaceutical ingredient under the condition 
that will lead to development of an optimal drug delivery system.  
7.2.1 Organoleptic Properties:  
 A small quantity of the drug powder was taken in butter paper and viewed 
in well-illuminated place for its colour, odour and taste. 
7.2.2 Solubility:  
 Saturation solubility of drug using different dissolution media was 
performed initially as well as after 24 hours. 
7.2.3 Melting Point: 
 Determination of melting point of the API sample was done using 
Differential Scanning Calorimeter using about 2 mg of API and empty pan as 
blank. 
7.2.4 X-Ray Diffraction Studies: 
 X-Ray diffraction studies were performed on the drug sample to know 
whether it is crystalline or amorphous by using X-Ray Diffractometer. 
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7.2.5 Hygroscopicity Studies: 
 It is based upon the determination of equilibrium moisture content of 
samples equilibrated at particular relative humidity (RH) using saturated salt 
solutions in the well of the desiccators. 
 2g of the drug powder was taken in each of 4 previously tarred Petri dishes 
and incubated in desiccators equilibrated at 25°C and 80% RH using saturated salt 
solution  of  ammonium  chloride.  The  samples  were  withdrawn  at  different  time  
points of 2, 4, 8 and 24 h and checked for % weight gain and loss on drying 
(LOD). The initial LOD of the sample was also noted. 
 
Table-12: Hygroscopicity classification criterion by sorption analysis. 
Hygroscopic class Criteria %w/w 
Non-hygroscopic < 0.2 
Slightly hygroscopic 0.2–2 
Hygroscopic/Moderately hygroscopic 2–15 
Very hygroscopic >15 
 
7.2.6 Sieve Analysis: 
 Average size of the API’s was determined using vibratory sieve shaker. 
50g of API was weighed and placed on an sieve shaker. The test was carried out 
at amplitude of 50 for 15 minutes. Percentage retained on each sieve #20, #30, 
#40, #60, #80, #100 and fines were determined. 
7.2.7 Moisture Content of API: 
 Moisture content of API was determined using Sartorius moisture analyzer 
with   1 g of powder sample at 105°C for 5 min.  From the readings obtained, the 
percentage loss on drying was calculated. 
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7.2.8 Density:  
7.2.8.1 Bulk Density:  
  An empty dry graduated 100 ml measuring cylinder was weighed 
accurately. 20 g of drug, which was previously passed through # 20 sieves, 
was transferred in the cylinder using a funnel. Powder was carefully leveled 
without compacting, and read the unsettled apparent volume (V0). The filled 
cylinder was again weighed and the difference between initial and final 
weight was calculated to get the exact weight of powder (M) in the cylinder. 
Apparent bulk density in g/ml was calculated by the following formula: 
 
Bulk density (BD) = Weight of powder (M) / Bulk volume (V0) 
 
7.2.8.2 Tapped Density:  
  Then the cylinder containing the sample was mechanically tapped 
by raising the cylinder and allowing it to drop under its own weight using USP 
I method on tapped density tester that provides a fixed drop of 14± 2 mm at a  
nominal rate of 300 drops per minute. 
  Cylinder was tapped for 500 times initially and then measured the 
tapped volume (V1) was measured to the nearest graduated units, tapping was 
repeated for an additional 750 times and tapped volume (V2) was measured to 
the nearest graduated units. If the difference between the two volumes is less 
than 2% then final the volume (V2) should be taken. 
The tapped density was calculated in g/ml by the following formula: 
 
Tapped Density (TD) = Weight of powder (M) / Tapped volume (V2) 
 
7.2.8.3 Compressibility Index: 
  The compressibility index of the powder blend was determined by 
Carr’s method. It is a simple test to evaluate the BD and TD of a powder and 
the rate at which it packed down. The formula for Carr’s Index is as below: 
 
Carr’s Index (%) = [(TD-BD) x100]/TD 
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7.2.8.4 Hausner’s Ratio: 
  The Hausner’s ratio is a number that is correlated to the flowability 
of a powder or granular material. 
 
Hausner’s Ratio = TD / BD 
 
Table-13: Effect of Carr’s Index and Hausner’s Ratio on flow property 
Carr’s Index (%) Flow Character Hausner’s Ratio 
< 10 Excellent 1.00–1.11 
11–15 Good 1.12–1.18 
16–20 Fair 1.19–1.25 
21–25 Passable 1.26–1.34 
26–31 Poor 1.35–1.45 
32–37 Very poor 1.46–1.59 
>38 Very, very poor >1.60 
 
7.2.8.5 Angle of Repose: 
  Angle of repose is a characteristic related to inter-particulate 
friction or resistance to movement between particles. The angle of repose is 
the constant three dimensional angle of a cone-like pile of material formed on 
a horizontal base. 
Angle of repose (θ) = tan -1 h/r 
Table-14: Flow property and corresponding angle of repose as per USP 
Flow Property Angle of Repose (degrees) 
Excellent 25 – 30 
Good 31 – 35 
Fair: aid not needed 36 – 40 
Passable: may hang up 41 – 45 
Poor: must agitate or Vibrate 46 – 55 
Very Poor 56 – 65 
Very, Very Poor > 66 
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7.2.9 Drug- Excipient Compatibility Study: 
 Drug - Excipients compatibility study was carried out by placing drug 
alone or drug along with excipients in certain ratio in stoppered vials at 40˚C/75% 
RH and 50˚C for one month. Analysis of related substances of the mixture was 
carried out at initial and after 1 month. 
Table-15: Drug-Excipient compatibility study 
S. No. Drug : Excipient Ratio 
1.  Glipizide 1 
2.  Glipizide + Polyethylene oxide (3 lakhs MW) 1:10 
3.  Glipizide + Polyethylene oxide (6 lakhs MW) 1:10 
4.  Glipizide + Polyethylene oxide (50 lakhs MW) 1:10 
5.  Glipizide + Polyethylene oxide (70 lakhs MW) 1:10 
6.  Glipizide + Micro Crystaline Cellulose 1:5 
7.  Glipizide + Sodium Chloride 1:5 
8.  Glipizide + Opadry CA 1:10 
9.  Glipizide + Iron oxide yellow 1:5 
10.  Glipizide + Opadry pink 1:10 
11.  Glipizide + Magnesium stearate 1:2 
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7.3 Characterization of Innovator Product:  
  The innovator product was tested for the following parameters. 
7.3.1 Physical Properties of Innovator: 
a) Description: The tablets were observed for their shape, color etc. 
b) Average weight (mg): 20 tablets were weighed and their average weight was 
calculated. 
c) Thickness (mm): Thickness of 10 tablets was measured using Vernier 
calipers. 
d) Dimension (mm): The diameters of 10 tablets were measured using Vernier 
calipers. 
e) Hardness (Newton): Tablets require a certain amount of strength or hardness 
and resistance to friability to withstand mechanical shocks. The hardness of 
tablet was measured by Varian hardness tester and results were expressed in 
kg/cm2 or kp. 
f) Other parameters like appearance, dosage form, batch no./lot no., expiry 
date, label claim, composition and storage recommendation were noted. 
7.3.2 Dissolution Profile: 
 The in-vitro dissolution studies were performed using OGD media. The 
formulation development work has been focused on matching the dissolution 
profile with the innovator in the OGD media. The dissolution media and method 
details are given in Table-16. 
Preparation of OGD Media:  
 For the preparation of 68.04 g of potassium dehydrogenate phosphate and 
9.25g of sodium hydroxide was weighed and dissolved well in 10 liters water. 
The pH was adjusted to 7.5 by 2M Sodium hydroxide. 
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Table-16: Dissolution method referred from OGD47 
Dissolution Medium 
Simulated intestinal fluid without 
Pancreatin, pH 7.5 
Apparatus USP – II 
RPM 50 
Media volume 900 ml 
Time interval 1,2,4,8,16 hours 
Temperature 370C ± 20C 
Condition Initial 
 
7.4 Analytical Method Parameters 
 
7.4.1 Standard Curve of Drug in Phosphate Buffer (pH 7.5): 
 It is one of the existing official drugs in USP. So, Based on these available 
information the drug detected at 276 nm λmax using UV spectrophotometer. 
Accurately 100 mg of drug was dissolved in pH 7.5 phosphate buffer solution 
[PBS] in a 100 ml volumetric flask and the volume was made up to volume. From 
this stock solution, solutions containing 5, 10, 15, 25, 30 and 35 mcg/ml were 
prepared. The absorbencies of the solutions were measured 
spectrophotometrically using UV-Visible spectrophotometer at 276 nm against 
phosphate buffer solution pH 7.5 as blank.  
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7.5 Formulation and Development of OCDDS:  
 Formulation development studies were conducted in a step-by-step manner 
observing product characteristics and performance parameters like dissolution profile. 
 
7.5.1 Calculation for the Quantity of Drug to be taken:  
The quantity of API was arrived by the below mentioned calculation. 
The assay as on such dried basis %w/w =  
 
= 
  
Actual API per tablet = Theoretical API weight per tablet × 100 / Assay as such 
basis 
Weight of the API was compensated with an equivalent weight of diluents. 
 
7.5.2 Selection of Excipient: 
 The selection of excipients was done considering the process selected                           
i.e. push-pull technology46,48. The grade, and physical characteristics and 
properties of the excipients were selected accordingly. All the excipients used in 
the development trials were suitable for compression. The results of the excipient 
compatibility with the proposed excipients, justified the selection of the 
formulation composition. 
    Assay on anhydrous basis x (100-LOD) 
    100 
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7.6 Manufacturing Procedure:  
  Based on patent review and literature manufacturing of bi-layered push pull osmotic 
tablet was done as follows 
Figure-26: Manufacturing procedure for push-pull osmotic tablet             
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7.7 Experimental Work: 
   
7.7.1 Procedure 
7.7.1.1 Drug / Pull Layer: 
a) Dry Mixing:  
 API, microcrystalline cellulose, poly ethylene oxide and sodium 
chloride were first passed through 40# sieve to separate the agglomerates 
if any. The sifted powder was then dry mixed in rapid mixer granulator for 
10 min. 
b) Binder Solution:  
 Hydro-alcoholic solution was directly used as the binder liquid. 
Since polyethylene oxide has good binding properties no other agent was 
added. Solution up to 30% of the weight was used as the binder liquid. 
c) Granulation:  
 Granulation is done by spraying the hydro-alcoholic solution for a 
period of 2 min and thereafter was knead for 2 min and 30 seconds. 
d) Drying:  
 Wet mass was then transferred to Retsch drier and then dried for a 
period of 45 min using following as the set parameter. 
Air flow - 40 
Temperature - 40ºC 
Time - 45 min   
 Drying was confirmed by subjecting it to LOD at a temperature of 
700C in auto mode. 
e) Sizing:  
 Dried granules were passed through 20# sieve. 
f) Lubrication:  
 The above granules were lubricated with magnesium stearate for a 
period of 3 min in blender at 10 rpm. 
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7.7.1.2 Push Layer: 
a) Dry Mixing:  
 Poly ethylene oxide, microcrystalline cellulose, sodium chloride 
and iron oxide were first passed through 40# sieve to separate the 
agglomerates if any. The sifted powder was then dry mixed in rapid mixer 
granulator for 10 min. 
b) Binder Solution:  
 Ethanol was directly used as the binder liquid. Since polyethylene 
oxide has good binding properties, no other agent was added. Solution up 
to 30% of the weight was used as the binder liquid. 
c) Granulation:  
 Granulation is done by spraying the ethanol solution for a period of 
2 min and thereafter was kneaded for 2 min and 30 seconds. 
d) Drying:  
 Wet mass was then transferred to Retsch drier and then dried for a 
period of 45 min using following as the set parameter. 
Air flow - 40 
Temperature - 40ºC 
Time - 45min 
Drying was confirmed by subjecting it to LOD at a temperature 
of 70ºC in auto mode. 
e) Sizing:  
 Dried granules were passed through 20# sieve. 
f) Lubrication: 
 The above granules were lubricated with magnesium stearate for a 
period of 3 min in blender at 10 rpm  
g) Compression:  
 The bi-layer tablet was compressed using the above prepared blend 
1 and blend 2 using a bi-layer rotary compression machine. Lubricated 
granules were compressed using 9.5 mm standard concave punches, plain 
on both the sides in rotary compression machine 
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Table-17: Compression machine parameters 
S.  No. Parameters Description 
1. Machine Cadmach 
2. Type of Tooling ‘’D’’ 
3. Punch shape Shallow concave 
4. Punch dimensions (mm) 9.5 mm 
5. No. of punches 1 
6. Speed (rpm) 20 
7 No. of Stations 16 
 
7.7.1.3 Coating: 
a) Preparation of Coating Solution:  
Ø Opadry CA: Coating solution was prepared by dissolving Opadry CA 
in a mixture of acetone and water (9:1) and subjected under stirring for 
a period of 45 min. 
Ø Opadry Pink: Colour coating solution was prepared by dissolving 
Opadry pink in water (1:10) and subjected under stirring for a period 
of 45 min. 
b) Coating Process:  
 Coating was performed by prepared solution of Opadry CA using 
Sams India coater machine by setting the following process parameters: 
 
Table-18: Coating machine parameters 
Inlet temperature 30ºC 
Bed temperature 28ºC 
Pan rpm 8 to 12 rpm 
Atomisation air pressure 2.0 psi 
  
 The average weight of the tablet was checked periodically to 
achieve required percentage weight gain. The coated tablet was allowed to 
dry at 400C in pan at 3 rpm. 
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c) Colour Coating:  
 Colour coating was performed by prepared solution of Opadry 
pink using Sams India coater machine by setting following process 
parameter. 
Table-19: Coating machine parameters 
Inlet temperature 50 ºC 
Bed temperature 45 ºC 
Pan rpm 8 to 12 rpm 
Atomisation air pressure 2.0 psi 
  
The average weight of the tablet was checked periodically to achieve 
required percentage weight gain. The coated tablet was allowed to dry at 
400C in pan at 3 rpm. 
d) Drilling of Orifice:  
 Orifice of diameter 0.5 mm was drilled on the push layer by using 
mechanical drill technology. 
e) In-Vitro Dissolution Study:  
 The prepared tablet was then subjected to in-vitro analysis to select 
the best formulation by matching it with innovator. 
7.8 Formulation Development: 
Trials were performed in two stages:  
7.8.1 Optimization of core tablet 
· Optimization of PEO in push and pull layer. 
· Optimization of osmogent in push layer. 
7.8.2 Optimization of Semi-permeable membrane in push layer. 
7.8.1 Optimization of Core Tablet 
7.8.1.1 Optimization of PEO in Pull and Push layer:  
  From the literature and through understanding of reverse 
technology by checking the viscosity of the reference product it was found 
that polyethylene oxide of low and high molecular weight was used in pull 
and push layer respectively. 
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 For optimization of pull layer, first low molecular weight polyethylene 
oxide (6 lakhs) was used with various concentrations initially from F1-F3 
trials, since the results were unsatisfactory to increase the drug release, it was 
replaced by polyethylene oxide (3 lakhs) and trials F4-F6 were performed.  
Similarly in push layer first high molecular weight polyethylene oxide (50 
lakhs) is used with various concentrations initially from trials F1-F6, since the 
drug release was slow, it was replaced by Polyethylene oxide (70 lakhs) and 
trials F7-F9 were performed. 
7.8.1.2 Optimization of Sodium Chloride in push layer:  
 Optimized trial F9 was taken, and to reduce the initial lag phase, trials F10 
and F11 were performed by decreasing and increasing the concentration of 
sodium chloride in push layers respectively. 
7.8.2 Optimization of Semi-Permeable Membrane:  
 Above optimized trial F11 was further selected for checking the effect of 
coating weight gain on drug release, trials F12, F13 and F14 were taken for 8%, 
10% and 12% weight gain respectively. 
7.9 Evaluation of Osmotic Tablets: 
7.9.1 Assay:  
 Twenty tablets of formulation were crushed into a fine powder by mortar 
and pestle, 100 mg of the crushed powder was weighed in 100 ml volumetric and 
diluted in a flask with 7.5 phosphate buffer. After sonication for 15 min the 
diluted solution was filtered. The total amount of drug for each tablet was 
analyzed using UV spectrophotometer. 
7.9.2 Weight Variation:  
 To study weight variation, 20 tablets of each formulation were weighed 
individually using a Sartorius electronic balance and compared with average 
value, the test was performed according to the official standards. 
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7.9.3 Hardness:  
 Ten tablets were randomly picked from each batch and checked for 
hardness using Varian hardness tester. 
7.9.4 Thickness: 
 Ten tablets from each batch were randomly picked and checked for 
thickness using digimeter vernier calipers. 
7.9.5 Friability:  
 Twenty tablets were weighed accurately and placed in the Electrolab 
friability apparatus. After 300 revolutions, the tablets were weighed and the 
percentage loss in tablet weight was determined. 
7.9.6 In-vitro drug release studies: 
 In-vitro release rate was tested using (USP-II) paddle type dissolution 
apparatus, using 900 ml of pH 7.5 phosphate buffer as dissolution medium at 
temperature 37º ± 2ºC. Samples were withdrawn at time intervals of 1, 2, 4, 8, and 
16 hours and analyzed spectrophotometrically. 
· For the final optimized formulation F14, the pre-compression parameter 
density and particle size distribution mentioned in pre-formulation studies 
were carried out. 
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7.10 Comparison of Dissolution Testing: 
 
The tablets, which are prepared by the finalized formula is compared with the innovator 
by means of dissolution.  
The method used for comparison of dissolution testing is model independent approach 
using difference factor f1.  
 
Formula for Difference factor (f1): 
 
f1={[∑t=1n|Rt-Tt|] / [∑t=1n Rt]}* 100 
 
 Where, n = number of dissolution sample times 
Rt and Tt is the individual or mean percent dissolved at each time point t, for the 
test and reference profiles respectively. 
 
Formula for Similarity factor (f2): 
 
f2 = 50 * log {[1+ (1/n) ∑t=1n (Rt-Tt) 2]-0.5 * 100 
 
A specific procedure to determine difference and similarity factors is as follows.  
 
Ø The dissolution profile of two products (12 units each) of the test (prepared 
tablets) and reference (innovator tablets) were determined..  
Ø Using the mean dissolution values from both curves at each interval, the 
difference factor (f1) and similarity factor (f2) using the above equations were 
calculated.  
Ø For curves to be considered similar, f1 values should be close to 0 and f2 values 
should be close to 100. Generally, f1 values up to 15 (0-15) and f2 values greater 
than 50 (50-100) ensure sameness or equivalence of the two curves i.e. 
performance of test and reference products is similar.  
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7.11 Stability Studies: 
  The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity, light and to establish a re-test period 
for the drug substance or a shelf-life for the drug product and recommended storage 
conditions.  
  The choice of test conditions defined in the guideline ICH – Q1A (R2) is based on 
an analysis of the effects of climatic conditions in the three regions of the EU, Japan and 
the United States. 
  The design of the formal stability studies for the drug product should be based on 
knowledge of the behavior and properties of the drug substance and from stability studies 
on the drug substance and on experience gained from clinical formulation studies.  
  The likely changes on storage and the rationale for the selection of attributes to be 
tested in the formal stability studies should be stated.  
 
7.11.1 Storage Conditions And Testing Frequency: 
 In general, a drug product should be evaluated under storage conditions 
(with appropriate tolerances) that test its thermal stability and, if applicable, its 
sensitivity to moisture or potential for solvent loss. The storage conditions and the 
lengths of studies chosen should be sufficient to cover storage, shipment, and 
subsequent use. 
Table-20: Stability study for trial batch 
Study Storage condition Time period 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 3 months 
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8. RESULTS 
8.1 Pre-Formulation studies: 
8.1.1 Organoleptic Properties:  
 The following organoleptic characters are observed with API 
Table-21: Organoleptic properties 
Color White to off white 
Taste Bitter 
Odour Characteristic 
 
8.1.2 Solubility:  
 The saturation solubility of the drug candidate is tabulated below 
Table-22: Solubility of the API in different media 
 
Type of 
Media 
 
mg dissolved per 100 ml 
Initial 24 hrs 
Individual Average Individual Average 
pH 5.5 
Phosphate 
buffer 
0.218 
0.3 
0.220 
0.356 
0.3 
0.357 
pH 6.8 
Phosphate 
buffer 
1.637 
1.6 
1.641 
1.488 
1.6 
1.490 
pH 7.5 
Phosphate 
buffer 
4.364 
4.5 
4.371 
4.531 
4.5 
4.549 
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8.1.3 Melting Point:  
  The DSC thermogram of glipizide exhibited a broad endothermic peak   at 
216.51°C   corresponding to its melting point of 216°C by using Universal V4.5A TA 
Instruments. 
 
 
Figure-27: DSC of Glipizide 
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8.1.4 X-ray Diffraction Study: 
 The X-ray diffraction pattern of powder sample was recorded on a scanning powder X-ray 
diffractometer. 
 
Figure-28: XRD graph of Glipizide 
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8.1.5 Hygroscopicity Studies: 
  As per the specifications of standards, hygroscopicity studies was carried 
out both in 25°C / 55% RH and 25°C / 80 % RH till 24 hours and the results are given 
in the following table. 
Table-23: Observations of the hygroscopicity studies 
Sr. No Parameter After 2
nd 
hrs % 
After 4th 
hrs % 
After 8th 
hrs % 
After 24th 
hrs % 
I Initial % LOD 0.59 0.59 0.59 0.59 
II RH 55% and  25°C 
1 % Weight gain 0.0 0.0 0.0 0.02 
2 % LOD at 105°C for 5 min 0.60 0.59 0.62 0.62 
III RH 80 %   and 25°C 
1 % Weight gain 0.0 0.0 0.01 0.025 
2 % LOD at 105°C for 5 min 0.59 0.60 0.59 0.63 
 
8.1.6 Sieve Analysis:  
  The data obtained from sieve analysis are tabulated below 
Table-24: Particle size distribution of the API 
Sieve no. Retention % w/w 
# 20 1 
# 30 3.2 
# 40 19.5 
# 60 54.8 
# 80 9.8 
# 100 2.6 
Through 100 8.6 
 
Results 	
 
 Page 85 
 
8.1.7 Moisture Content of API: 
 Moisture content of the API by loss on drying was found to be 0.15% w/w. 
8.1.8 Density: 
Table-25: Physical characteristics of the API 
S. No. Parameter Value 
a) Bulk density 0.17gm/ml 
b) Tapped density 0.28 gm/ml 
c) Carr’s index 39.28 
d) Hausner ratio 1.65 
e) Angle of repose 44.13º 
 
8.1.9 Drug-Excipient Compatibility Study: 
 The drug-excipients compatibility study carried out at 40˚C/75% RH for one 
month and the results are given below in table below. The physical appearance and 
assay of the mixture was carried out at initial and after 1 month. 
Table-26: Drug-Excipient compatibility  
S. No. Drug-Excipient Ratio Condition Physical Appearance Assay (%) 
1.  API 1 
Initial White to off 
white powder 99.6 
40º/75%  for 
1 Month No Change 98.40 
2.  API + PEO (6 lakh MW) 1:10 
Initial White to off 
white powder 99.6 
40º/75%  for 
1 Month No Change 96.4 
3.  API + PEO (3 lakhs MW) 1:10 
Initial White to off 
white powder 99.6 
40º/75%  for 
1 Month No Change 98.6 
4.  API + PEO (50 lakhs MW) 1:10 
Initial White to off 
white powder 99.6 
40º/75%  for 
1 Month No Change 97.8 
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S. No. Drug-Excipient Ratio Condition Physical Appearance Assay (%) 
5.  API + PEO (70 lakhs MW) 1:10 
Initial White to off 
white powder 99.6 
40º/75%  for 
1 Month No Change 98.4 
6.  API +MCC 1:10 
Initial White crystalline 
powder 99.6 
40º/75%  for 
1 Month No Change 96.8 
7.  API + Sodium Chloride 1:5 
Initial White crystalline 
powder 99.6 
40º/75%  for 
1 Month No Change 98.8 
8.  API + Opadry CA 1:10 
Initial White to off 
white powder 99.6 
40º/75%  for 
1 Month No Change 97.4 
9.  API + Yellow Iron oxide 1:2 
Initial Yellow powder 99.6 
40º/75%  for 
1 Month No Change 97.6 
10.  API + Opadry pink 1:10 
Initial Pink powder 99.6 
40º/75%  for 
1 Month No Change 98.4 
11.  
API + 
Magnesium 
stearate 
1:1 
Initial White crystalline 
powder 99.6 
40º/75%  for 
1 Month No Change 98.5 
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8.2 Characterization of Innovator Product: 
8.2.1 Physical Properties of Innovator: 
Table-27: Physical properties of innovator product 
 
 
S. No. Parameters Innovator / Reference 
1 Label Claim Each Tablet contains 10 mg  of Glipizide 
2 Dosage form Extended  Release tablet 
3 Batch No: / Lot No. V130480 
4 Expiry Date May-17 
5 Strength 10 mg/Tablet 
6 Package insert Available 
7 Primary pack HDPE container 
8 Secondary pack No 
9 Composition 
Polyethylene oxide, hypromellose, 
magnesium stearate, sodium chloride, red 
ferric oxide, cellulose acetate, polyethylene 
glycol, Opadry® white 
10 Storage Store at 15-300C (59-860F) 
11 
Appearance 
[Embossing and break line 
details to be included] 
White colored with no embossing 
imprinted GXL 10 on one side. 
12 Average weight (mg) 392.25 
13 Average thickness (mm) 5.55 
14 Average diameter (mm) 9.82 
15 Orifice diameter (mm) 0.43 
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Figure-29: Physical appearance of innovator tablet 
 
 
 
 
Figure-30: Primary pack of innovator product 
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8.2.2 Dissolution Profile of Innovator: 
 
 
Table-28: Dissolution profile of the marketed product 
Time (h) Percentage drug released 
0 0 
2 1 
4 17 
8 47 
16 99 
20 100 
24 100 
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Figure-31: Innovators dissolution profile 
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8.3 Analytical Method Parameters: 
 
Table-29: Calibration curve of Glipizide in pH 7.5 phosphate buffer at λmax 276 nm 
Concentration Absorbance 
0 0 
5 0.145 
10 0.255 
15 0.362 
20 0.469 
25 0.625 
30 0.772 
 
 
Calibration Curve of glipizide in pH 7.5 phosphate 
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Figure-32: Calibration Curve of Glipizide 
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8.4 Formulation and Development of OCDDS:  
 
8.4.1 Calculation for Quantity of Drug to be taken:  
Assay on anhydrous basis (% w/w) = 99.60% 
LOD/ water by Karl Fischer % w/w = 0.15% 
The Assay as on such dried basis %w/w =  
 
= 99.45% 
Actual API per tablet = Theoretical API weight per tablet × 100/Assay as such 
basis 
= 10.06 mg 
Weight of the API was compensated with an equivalent weight of diluents. 
 
8.4.2 Selection of Excipient: 
The excipients were selected based on the available patent and literature support. 
Following excipients were considered. 
ü Poly Ethyelene Oxide (6 lakhs MW) 
ü Poly Ethyelene Oxide (3 lakhs MW) 
ü Poly Ethyelene Oxide (50 lakhs MW) 
ü Poly Ethyelene Oxide (70 lakhs MW) 
ü Sodium chloride 
ü Microcrystalline Cellulose 
ü Magnesium stearate 
ü Iron oxide yellow 
ü Opadry CA 
ü Opadry pink 
 
8.5 Formulation Development: 
8.5.1 Optimization of Core Tablet: 
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8.5.1.1 Optimization of Poly Ethylene Oxide in Push and Pull layer: 
Table-30: Optimization of Polyethylene oxide in Pull and Push layers 
Pull layer ( drug layer) 
Ingredients (mg) F1 F2 F3 F4 F5 F6 
Glipizide 10.06 10.06 10.06 10.06 10.06 10.06 
Polyethylene 
oxide 
(6 lakhs MW) 
145 160 175 --- --- --- 
Polyethylene 
oxide 
(3 lakhs MW) 
--- --- --- 145 160 175 
Sodium chloride 10 10 10 10 10 10 
MCC 45 30 15 45 30 15 
Magnesium  
Stearate 1 1 1 1 1 1 
Total 211.06 211.06 211.06 211.06 211.06 211.06 
Push layer 
Polyethylene 
oxide  
 (50 lakhs MW) 
85 85 85 85 85 85 
Sodium chloride 30 30 30 30 30 30 
MCC 15 15 15 15 15 15 
Iron oxide 
Yellow 1 1 1 1 1 1 
Magnesium  
Stearate 1 1 1 1 1 1 
Total 132 132 132 132 132 132 
Coating of Semi-Permeable membrane (14% gain) 
Opadry CA 48 48 48 48 48 48 
Total 391.06 391.06 391.06 391.06 391.06 391.06 
Colour coat (3% weight gain) 
Opadry pink 11.7 11.7 11.7 11.7 11.7 11.7 
Total 402.76 402.76 402.7 402.76 402.76 402.76 
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8.5.1.2 Optimization of Poly Ethylene Oxide and Osmogent in Push Layer: 
Table-31: Optimization of poly ethylene oxide and sodium chloride in Pull and Push layers 
Pull layer ( drug layer) 
Ingredients (mg) F7 F8 F9 F10 F11 
Glipizide 10.06 10.06 10.06 10.06 10.06 
Polyethylene 
oxide 
  (3 lakhs MW) 
175 175 175 175 175 
Sodium chloride 10 10 10 10 10 
MCC 15 15 15 15 15 
Magnesium  
stearate 1 1 1 1 1 
Total 211.06 211.06 211.06 211.06 211.06 
Push layer 
Polyethylene 
oxide  
 (70 lakhs MW) 
80 85 90 90 90 
Sodium chloride 30 30 30 20 40 
MCC 20 15 10 20 0 
Iron oxide Yellow 1 1 1 1 1 
Magnesium  
Stearate 1 1 1 1 1 
Total 132 132 132 132 132 
Coating of Semi-Permeable membrane (14% gain) 
Opadry CA 48 48 48 48 48 
Total 391.06 391.06 391.06 391.06 391.06 
Colour coat(3% weight gain) 
Opadry pink 11.7 11.7 11.7 11.7 11.7 
Total 402.76 402.76 402.76 402.76 402.76 
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8.5.1.3 Optimization of Semi-Permeable Membrane in Push Layer. 
Table-32: Optimization of semi-permeable membrane 
Pull layer(drug layer) 
Ingredients (mg) F12 F13 F14 
Glipizide 10.06 10.06 10.06 
Polyethylene oxide 
(3 lakhs MW) 
175 175 175 
Sodium chloride 10 10 10 
MCC 15 15 15 
Magnesium  Stearate 1 1 1 
Total 211.06 211.06 211.06 
Push Layer 
Polyethylene oxide 
(70 lakhs MW) 90 90 90 
Sodium chloride 40 40 40 
MCC 0 0 0 
Iron oxide Yellow 1 1 1 
Magnesium Stearate 1 1 1 
Total 132 132 132 
Coating of Semi-Permeable membrane 
 8% 10% 12% 
Opadry CA 27.4 34.3 41.1 
Total 370.46 377.36 384.16 
Colour coat (3% weight gain) 
Opadry pink 11.1 11.3 11.5 
Total 381.56 388.66 395.66 
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Figure-33: Side view of uncoated bi layered, Semi-permeable membrane coated, Top coated 
osmotic tablets 
 
 
Figure No 34: Top view of coated osmotic tablet with drilling 
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8.6 Evaluation of Osmotic Tablets: 
8.6.1 Compression Parameters 
Table-33: Compression parameters of trials F1-F14 
Batch  
No. 
Assay (%) 
Average 
Weight             
(Bi-layer 
tablet) mg 
Hardness 
(kp) 
Thickness 
(mm) 
Friability 
(%) 
Weight 
variation 
F1 98.06 341.3 ± 0.56 13 ± 0.26 4.95 ± 0.13 0.118 Complies 
F2 102.3 343.8 ± 1.26 14 ± 0.36 4.92 ± 0.24 0.137 Complies 
F3 99.1 344.8 ± 1.53 14.8 ± 0.4 4.93 ± 0.19 0.154 Complies 
F4 103.2 343.4 ± 0.29 14 ± 0.28 4.93 ± 0.26 0.241 Complies 
F5 101.0 341.6 ± 2.10 13 ± 0.40 4.94 ± 0.22 0.148 Complies 
F6 98.7 342.6 ± 0.12 13.6 ± 0.25 4.93 ± 0.16 0.160 Complies 
F7 102.07 342.8 ± 2.01 13.5 ± 0.33 4.90 ± 0.28 0.213 Complies 
F8 98.6 344.8 ± 1.02 14.8 ± 0.38 4.91 ± 0.22 0.256 Complies 
F9 99.8 341.2 ± 2.06 13 ± 0.22 4.92 ± 0.17 0.222 Complies 
F10 96.7 345.4 ± 0.75 15 ± 0.28 4.91 ± 0.15 0.157 Complies 
F11 100.8 341.5 ± 1.96 13 ± 0.40 4.90 ± 0.23 0.250 Complies 
F12 98.6 342.2 ± 1.25 13.8 ± 0.62 4.93 ± 0.15 0.231 Complies 
F13 101.2 343.6 ± 0.46 14 ± 0.23 4.95 ± 0.13 0.168 Complies 
F14 99.05 341.3 ± 0.26 13 ± 0.26 4.96 ± 0.08 0.226 Complies 
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8.6.2 In- Vitro Dissolution of Push-Pull Osmotic Drug Delivery System:-  
 
The results of dissolution profile for the various formulations trials for bi-layer 
osmotic drug delivery system are as follows 
 
 
8.6.2.1 Optimizations of Poly Ethylene Oxide in Pull and Push Layer 
 
Table-34: Percentage cumulative drug release data 
Time 
(h) Innovator F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 
2 1 1 2 1 1 1 1 
4 17 10 13 11 9 10 13 
8 47 24 30 25 28 32 28 
16 99 45 48 55 74 70 77 
20 100 55 58 63 77 77 82 
24 100 56 62 65 78 80 84 
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Figure-35: Percentage cumulative drug release against  time graph  
.  
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8.6.2.2 Optimizations of Poly Ethylene Oxide in Pull and Push Layer:- 
 
 
Table-35: Percentage cumulative drug release data  
Time 
(h) Innovator F7 F8 F9 
0 0 0 0 0 
1 0 0 0 0 
2 1 1 1 1 
4 17 7 9 10 
8 47 28 26 33 
16 99 68 77 93 
20 100 82 91 96 
24 100 84 92 96 
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Figure-36: Percentage cumulative drug release against time graph 
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8.6.2.3 Optimization of Sodium chloride in Push Layer:- 
Table-36: Percentage cumulative drug release data  
Time (h) Innovator F10 F11 
0 0 0 0 
1 0 0 0 
2 1 1 1 
4 17 8 15 
8 47 30 46 
16 99 93 99 
20 100 95 99 
24 100 96 100 
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Figure-37: Percentage cumulative drug release against  time graph 
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8.6.2.4 Optimization of Semi-Permeable Membrane Coating:- 
Table-37: Percentage cumulative drug release data  
Time (h) Innovator F12 F13 F14 
0 0 0 0 0 
1 0 6 2 0 
2 1 9 4 1 
4 17 30 22 17 
8 47 62 56 49 
16 99 100 100 99 
20 100 100 100 100 
24 100 100 100 100 
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Figure-38: Percentage cumulative drug release against  time graph 
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8.6.2.5 Comparison of Formulation F11 and Formulation F14: 
Table-38: Percentage cumulative drug release data  
Time (h) Innovator F11 F14 
Coating of                     
Semi-permeable 
membrane 
14% 12% 
0 0 0 0 
1 0 0 0 
2 1 1 1 
4 17 15 17 
8 47 46 49 
16 99 99 99 
20 100 99 100 
24 100 100 100 
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Figure-39: Percentage cumulative drug release against  time graph 
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8.7 Dissolution Profile Comparison (Test formulation against Reference formulation): 
8.7.1 Test formulation F14 against Reference formulation: 
Table-39: Comparison of Dissolution profile of test vs reference 
Time (h) Rt Tt |Rt-Tt| |Rt-Tt|2 
0 0 0 0 0 
2 1 1 0 0 
4 17 17 0 0 
8 47       49 2 4 
16 99 99 0 0 
20 100 100 0 0 
24 100 100 0 0 
Total 364 366 2 4 
    
 f1 = {[∑t=1n|Rt-Tt|] / [∑t=1n Rt]}* 100 
       = 1 
   f2 = 50 * log {[1+ (1/n) ∑t=1n (Rt-Tt) 2]-0.5 * 100 
       = 92 
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8.7.2 Test formulation F11 against Reference formulation: 
Table-40: Comparison of Dissolution profile test vs standard 
Time (h) Rt Tt |Rt-Tt| |Rt-Tt|2 
0 0 0 0 0 
2 1 1 0 0 
4 17 15 0 0 
8 47 46 2 4 
16 99 99 0 0 
20 100 99 0 0 
24 100 100 0 0 
Total 364 360 2 4 
    
 f1 ={[∑t=1n|Rt-Tt|] / [∑t=1n Rt]}* 100 
       = 1.10 
   f2 = 50 * log {[1+ (1/n) ∑t=1n (Rt-Tt) 2]-0.5 * 100 
       = 93 
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8.8 Physical Characteristics of Optimized Formulation. 
8.8.1 Physical Characteristics of Lubricated Blend F14: 
The physical characteristic and particle size analysis of lubricated blend was 
studied and listed below. 
Table-41: Physical characteristics of lubricated blend F14 
Parameters Pull layer Push layer 
Bulk density (g/ml) 0.45 0.511 
Tapped density (g/ml) 0.52 0.58 
Carr’s index (%) 14.2 12.3 
Hausner’s ratio 1.15 1.14 
Angle of repose 26.57 24.7 
 
Table-42: Particle size analysis results 
Sieve 
Number 
Percentage weight retained on sieve 
Pull layer Push layer 
20 0 0.4 
30 5.6 2 
40 7.9 3.2 
60 20.2 33.6 
80 21.4 21 
100 10.9 8.2 
Pan 33.8 31.6 
 
8.8.2 Physical Characteristics of Coated Tablets of F14 Batch: 
The physical characteristics of the coated tablets of formulation F14 was studied 
and listed below. 
Table No. 43: Physical characteristics of the coated tablets of F14 batch 
S. No. Parameters F14 
1 Average weight 396.8+1.96 
2 Friability (%) 0.19 
3 Hardness (kp) 25 ± 2.1 
4 Thickness (mm) 5.66 ± 0.06 
5 Average diameter 9.0 ± 0.8 
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Figure-40: Optimized batch (F14) Osmotic tablets 
 
8.9 Stability Data of Optimized Formulation: 
  The samples of F14 batch were kept under 40ºC/75% RH condition for 1 month. 
The Physical appearance, assay and dissolution profile of initial and 1 month data were 
studied and listed below. 
Table-44: Stability data of F14 batch 
 
S. No 
 
Test 
 
Initial 
 
40ºC/75% RH 
1 month 
 
40ºC/75% RH 
3 month 
1.  Physical Appearance 
Pink coloured 
smooth faced 
tablet 
No Change No Change 
2.  Assay (%) 99.05 99.56 100.20 
3.  
 
Dissolution 
release 
profile (%) 
2 hrs 1 ± 0.58 1 ± 0.58 2 ± 0.58 
8 hrs 49 ± 5.69 50 ± 4.04 48 ± 6.51 
16 hrs 99 ± 1.15 97 ± 3.06 98 ± 2.08 
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9. DISCUSSION 
9.1 Pre-Formulation Studies: 
9.1.1 Organoleptic Properties:  
  The organoleptic properties of active pharmaceutical ingredient of this 
study (Glipizide) was studied and found to be White to off white in colour, bitter in 
taste and odourless. 
9.1.2 Solubility:  
  The saturation solubility of the drug candidate is tabulated in Table 22. 
The solubility study of glipizide was carried out and it was observed that it has pH 
dependent solubility, soluble in pH 7.5. Also literature survey reveals that glipizide 
is a highly permeable drug. Hence it was concluded that model drug belongs to 
BCS class II i.e. it has low solubility and high permeability. 
9.1.3 Melting Point:  
  The  DSC  thermogram  (Figure  27)  of  glipizide  exhibited  a  broad  
endothermic peak   at 216.51°C   corresponding to its melting point of 216°C by 
using Universal V4.5A TA Instruments. Therefore it was concluded that exposure 
to high temperature should be avoided and the loss on drying percentage of the 
blends prepared should be taken at temperature fairly below the melting point of the 
drug.  
9.1.4 X-ray Diffraction Study: 
  X- ray powder diffraction patterns were recorded (Figure 28) using X-ray 
Diffractometer, D8 Advanced, Bruker AXS, Germany. The scanning rate used was 
1o.  2θ/min  over  the  range  3  to  50.   The  X-ray  diffraction  pattern  showed  that  
glipizide is crystalline in nature. 
9.1.5 Hygroscopicity Studies: 
  Hygroscopicity studies was carried out both in 25°C/55% RH and 
25°C/80% RH till 24 hours. 
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  As  per  standard,  increase  in  weight  gain  was  within  limits  and  as  
percentage weight gain of glipizide was found to be 0.02% and 0.025% at RH 50% 
and 80% after 24 hours respectively (Table 23), Thus glipizide was found to be 
non-hygroscopic in nature. 
9.1.6 Sieve Analysis:  
  From the sieve analysis result listed in Table 24, it was found that majority 
of the particles lie above sieve no #60 (250 µm). 
9.1.7 Moisture Content of API: 
  Moisture content of the glipizide by Loss on Drying was found to be                   
0.15% w/w. 
9.1.8 Density: 
  The values of Carr’s index, Hausner ratio and angle of repose showed that 
the glipizide powder has very poor flow (Table 25). 
9.1.9 Drug-Excipient Compatibility Study: 
  The excipients compatibility study results (Table 26) showed that the 
assays of the mixture were within specified limits and no physical changes were 
observed. Thus all the above excipients were said to be compatible with glipizide 
and can be used in formulation development. 
9.2 Characterization of Innovator Product: 
9.2.1 Physical Properties of Innovator: 
  Physical properties of innovator product were noted and listed in                 
Table-27. 
9.2.2 Dissolution Profile of Innovator  
  The dissolution of the innovator Tablet was done in USFDA 
recommended media (simulated intestinal fluid without pancreatin, pH 7.5) and the 
percentage drug released is tabulated in Table 28. 
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9.3 Analytical Method parameters: 
9.3.1 Calibration Curve of Glipizide in pH 7.5 Phosphate Buffer 
Placebo Interference:  
  The placebo solution does not show any peak at the λmax of standard 
solution of the model drug. Therefore no placebo interference was encountered 
during the dissolution of prototype formulation.  
Inference: 
  The λmax of glipizide was observed at about 276 nm. Considering this λmax, 
a calibration curve of glipizide was plotted (Figure 32). The standard graph 
constructed conferred that the concentrations of drug ranging from 5 to 30 µg/ml 
obeyed the Beer-Lambert’s Law principle.  Moreover, the calibration curve 
exhibited a good correlation between the concentrations and the absorbance in this 
range (R2 = 0.9953). 
9.4 Evaluation of Osmotic Tablets: 
9.4.1 Compression Parameters: 
  It was evident from the Table 33 that all the trial formulations comply 
with the standard specification mentioned in the USP for assay, average weight, 
weight variation and friability. Also the thickness and hardness parameters of the 
prepared Tablets complied with the in house specifications. The orifice diameter 
was found to be in the range of 0.53 to 0.56 mm. 
9.4.2 In-Vitro Dissolution of Push-Pull Osmotic Drug Delivery System: 
  Dissolution profile results for the various formulation trials of push and 
pull technique based osmotic drug delivery system are as follows: 
9.4.2.1 Optimizations of PEO in Pull and Push Layer: 
 Among the formulations, F1 to F6 when compared with innovator 
(Table 34), the results of percentage cumulative release of formulation F5 
and F6 showed good zero-order release kinetics (Figure 35). F6 showed a 
Discussion	
 
 Page 109 
 
higher percentage cumulative release compared to F5 and also F6 showed 
a release profile closer to the innovator.  
9.4.2.2 Optimizations of PEO in Pull and Push Layer: 
 Based on dissolution profile of the trials of F7 to F9 (Table 35), it 
was found that as the concentration of PEO in the push layer is increased, 
cumulative percentage of the drug release is also increased. From the 
above trials it was found that formulation F9 showed good zero-order 
release kinetics. Since F9 showed a good percentage cumulative release 
close to innovator, it was selected for further optimization (Figure 36). 
9.4.2.3 Optimization of Sodium Chloride in Push Layer: 
 After optimizing the Sodium chloride in push layer, the dissolution 
profile of formulation F10 and F11 clearly showed that when the 
concentration of sodium chloride in push layer is increased, the initial drug 
release was increased (Table 36 and Figure 37). Among, F10 and F11, 
formulation F11 showed release rate closer to innovator and had greater f2 
value.  As the f2 and the dissolution profile showed positive signs among 
other formulation, F11 formulation was taken as the final core formula.  
9.4.2.4 Optimization of Semi-Permeable Membrane Coating: 
 To investigate the role of semi-permeable membrane in the 
formulation, three formulations with 8%, 10% and 12% were formulated 
and evaluated.  From the results in Figure 38, it was seen that all the 
formulation showed good zero order release kinetics. Formulations F12 
and F13 showed faster percentage drug release compared with formulation 
F14 (Table 37). However formulation F14 showed similar release profile 
when compared with innovator. 
9.4.2.5 Comparison of Formulation F11 and Formulation F14: 
 When the release profile of formulation F11 and F14 were 
compared against the innovator, the release was found to be similar (Table 
38). Increase in coating (i.e. more than 14%) in semi permeable membrane 
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may further decrease the release profile. Correspondingly, decrease in 
coating (i.e. 8 to 10%) showed faster profile compared with that of 
innovator (Formulation F12 and F13).  
The Formulation F14 with 12% coating and F11 with 14% coating were 
closer to the release profile of reference formulation (Figure 39), therefore 
a coating of 13±1% will suffice to meet the study requirements. 
9.5 Dissolution Profile Comparison (Test product vs. Reference product): 
 As formulations F11 and F14 % had cumulative percentage drug release were 
closer to the innovator release profile, they both were selected for finding out the difference 
factor (f1) and similarity factor (f2). 
  The f1 and f2 values obtained from both formulations were within the limits. So 
the prepared F11 and F14 formulations were found to be equivalent with innovator. More 
specifically F14 shows the better closeness to the innovator product.   
  As both F11 and F14 are having the same composition in the core Tablet and they 
vary in coating of semi permeable membrane with 2% each, optimum range for the coating 
of semi-permeable membrane can be considered as 13±1%. 
 But, to avoid extra weight gain when compared to other formulations,  12% is 
selected as optimized weight gain, concluding F14 as optimized formulation and 
continuing further studies to scale-up formulations.  
9.6 Physical Characteristics of Optimized Formulation: 
9.6.1 Physical Characteristics of Lubricated Blend F14: 
  The physical characteristic of lubricated blend of F14 was studied and 
listed (Table 41). Both the push layer and pull layer blends were found to have good 
flow property.  
9.6.2 Physical Characteristics of Coated Tablets of F14 Formulation: 
  The average weight, friability, hardness, thickness and average diameter of 
the coated Tablets of f14 formulation were studied and they were found to be 
acceptable (Table 43).  
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9.7 Stability Data of Optimized Formulation: 
  Optimized formulation was kept for stability studies and checked for the 
appearance, assay, and dissolution profile after 1 and 3 months (Table 44). There were no 
significant changes in in-vitro release profile. Thus, formulation F14 was found to be stable 
with respect to our desired parameters.  
Summary and Conclusion	
 
Page 112 
 
10. SUMMARY AND CONCLUSION 
 
 The aim of the present study was to formulate and evaluate a generic osmotic controlled 
delivery system for an innovator’s anti-diabetic drug. Osmotic devices are most promising 
strategy based systems for controlled drug delivery. They are among the most reliable controlled 
drug delivery systems and could be employed as oral drug delivery systems or implantable 
devices. Extended release formulation of an anti-diabetic drug based on push pull osmotic 
technology was developed and evaluated. The effect of different formulation variable namely, 
amount of PEO in push and pull layers, effect of various grades of PEO in push and pull layers, 
amount of sodium chloride in push layer, semi permeable membrane weight gain, were studied.  
 
 Bi-layer push-pull osmotic tablets were prepared using polyethylene oxide as an 
expanding agent. Tablets were coated with semi permeable membrane using Opadry CA and 
mechanically drilled; in vitro drug release was performed in US food and drug administration 
recommended official dissolution media pH 7.4 phosphate buffer to study the drug release 
profile. 
 
 From formulations F1 to F3, poly ethylene oxide of molecular weight 6 lakhs and poly 
ethylene oxide of molecular weight 50 lakhs were used in pull and push layers respectively with 
varying concentrations, the drug release profile showed very slow release. To enhance the drug 
release, formulations F4 to F6 were formulated using poly ethylene oxide of 3 lakhs molecular 
weight, which is of low molecular weight when compared to previous formulation. When poly 
ethylene oxide of 50 lakhs was used in push layer, the release profile showed good zero-order 
release but the drug release was slow compared with that of innovator.  
 
 To enhance the drug release further, formulations F6 to F9 were done using PEO of 
higher molecular weight, 70 lakhs in push layer, and PEO of 3 lakhs molecular weight in pull 
layer. It showed good release profile similar to innovator, but initial drug release was slow. 
Formulations F10 and F11 were performed to overcome the initial slow release of drug, by 
varying concentration of sodium chloride in push layer. By increasing the concentration of 
Sodium chloride the drug release was increased and the release profile was similar to innovator.  
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 All the above formulations were performed by coating with Opadry CA (a ready 
formulated semi permeable membrane coating system comprising CA and PEG3350) as semi 
permeable membrane to get a 14% weight gain, based on information available from patent and 
literature. To check the effect of weight gain, formulations F12, F13, F14 were formulated by 
coating with Opadry CA to obtain, 8%, 10%, 12% weight gain respectively. Formulation F12 
and F13 with 8% and 10% showed fast release, whereas, the formulation F14 with 12 % showed 
similar release when compared with innovator. The comparative release profile of formulations 
with 12% and 14% showed similar release profile when compared with innovator. So, coating of 
semi-permeable membrane of 13±1% can be recommended to get the desired release profile. 
But, to avoid extra weight gain when compared to other formulations,  12% was selected as 
optimized weight gain, concluding F14 as optimized formulation and continuing further studies 
to scale-up formulations.  
 
 Stability studies were conducted at 40ºC/75% RH for 3 months. Physical appearance, 
assay and dissolution profile of optimized formulation F14 complies with Innovator product and 
was found to be stable. 
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